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The worldwide prevalence of obesity has nearly doubled between 1980 and 
2008 (Finucane et al 2011). Globally, 35% of adults aged ≥20 years were over-
weight (BMI ≥25 kg/m2) and 11% were obese (BMI ≥30 kg/m2) in 2008. Over-
weight and obesity are linked to more deaths worldwide than underweight 
(World Health Organization 2013). The rapid increase in worldwide rates of 
overweight and obesity over the last 30–40 years suggests a predominant 
change in environmental, diet, and lifestyle factors rather than any change in 
genetics as the main cause of the obesity epidemic. On the other hand, the 
observation that the loss of the function of certain genes in human leads to 
either severe obesity, early diabetes, or severe insulin resistance challenges the 
view that environmentally driven obesity leads to insulin resistance which leads 
to type 2 diabetes (Murphy et al 2013). However, there is a wide spectrum 
ranging from genetically determined obesity to behaviourally determined obe-
sity, while in most individuals these factors are mixed (gene-environment inter-
action) (Clement et al 2010). Obesity is associated with hypertension, diabetes, 
hyperlipidaemia, coronary heart disease, liver disease, heart failure, respiratory 
failure, asthma, cholelithiasis, osteoarticular diseases, and cancers as well as 
with psychological disorders such as depression, which reduce the quality and 
length of life (Clement et al 2010). Many of the comorbidities of obesity are 
reflected in metabolic syndrome (Haslam et al 2005). The metabolic syndrome 
is a clustering of risk factors (glucose intolerance, obesity, elevated blood pres-
sure and dyslipidaemia) which predispose an individual to cardiovascular mor-
bidity and mortality (Day 2007). Obesity is the most important modifiable risk 
factor before metabolic syndrome develops and central obesity precedes 
deterioration in each of the components that consitute the metabolic syndrome 
(Cameron et al 2009). However, a subset of obese subjects seems to be pro-
tected from obesity-related cardiovascular and cardiometabolic abnormalities 
and this obesity phenotype is described as metabolically normal obesity or 
metabolically healthy obesity (Pataky et al 2010).  
Insulin resistance is implicated in the pathophysiology of the twin epidemic 
of type 2 diabetes and obesity (Murphy et al 2013). There is no universally ac-
cepted key mechanism underlying metabolic syndrome, although insulin resis-
tance and central obesity have both been proposed for this role (Simmons et al 
2010).  
Adipose tissue modulates metabolism by releasing non-esterified fatty acids 
and glycerol, and hormones including leptin and adiponectin, as well as proin-
flammatory cytokines (Kahn et al 2006). Adiponectin has insulin-sensitizing, 
anti-inflammatory, anti-atherogenic and cardioprotective properties and, unlike 
most other adipokines, circulating levels of adiponectin are reduced in obesity 
and associated diseases (Scherer 2006). Adiponectin is secreted into the cir-
culation as low-molecular-weight (trimers and hexamers) and high-molecular-
weight (HMW) multimers with the latter being more metabolically active 
(Simpson et al 2010). There is a clear gender difference in HMW adiponectin 
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levels: women have significantly higher HMW adiponectin concentration com-
pared with men, whereas there were no gender differences for the other two 
forms (Xu et al 2005). Certain obese individuals have adiponectin levels similar 
to those found in subjects with normal body mass index (BMI), which is 
associated with the metabolically healthy obese phenotype (Aguilar-Salinas et 
al 2008). Data about HMW adiponectin levels in metabolically healthy obese 



























4. REVIEW OF THE LITERATURE 
4.1. Definitions of overweight and obesity,  
imapired glucose regulation and metabolic syndrome 
4.1.1. Definitions of overweight and obesity 
According to the World Health Organization (WHO), obesity is defined as a 
condition of abnormal or excessive fat accumulation in the adipose tissue, to the 
extent that health may be impaired (World Health Organization 2000). Of the 
five anthropometric indices for diagnosing obesity – BMI, body fat percentage, 
waist circumference, waist-to-hip ratio and waist-to-stature ratio – the most 
commonly used index around the world is BMI (Cheng 2004). BMI is a simple 
index of weight-for-height that is commonly used to classify overweight and 
obesity in adults. It is defined as a person`s weight in kilograms divided by the 
square of his\her height in meters (kg/m2). The classification of overweight and 
obesity according to BMI is shown in Table 1 (World Health Organization 
2000). Obesity is defined as a BMI ≥ 30.0 (World Health Organization 2000).  
 
 
Table 1. WHO classification of adults according to BMI 
Classification BMI Risk of comorbidities 
Underweight <18.5 Low (but increased risk of other clinical 
problems) 
Normal range 18.5–24.9 Average 
Overweight ≥25.0  
Preobese 25.0–29.9 Increased 
Obese class I 30.0–34.9 Moderate 
Obese class II 35.0–39.9 Severe 
Obese class III ≥40.0 Very severe 
 
 
Although BMI is a convenient tool to define obesity it does not take into account 
body composition (fat mass and fat-free mass distribution) (World Health 
Organization 2000, Clement et al 2010, Gomez-Ambrosi et al 2012). A recent 
cross-sectional study from Spain showed that 29% of subjects classified as lean 
and 80% of individuals classified as overweight (pre-obese) according to BMI 
had body fat percentage (estimated by air displacement plethysmography) within 
the obesity range (≥25.0% for men and ≥35.0% for women). Thus BMI, although 
being an extremely valuable tool for epidemiological studies, may underestimate 
body fat percentage, especially in the overweight category, and the actual cut-off 
points that can more accurately diagnose obesity may be different: 29 kg/m2 for 
men and 27 kg/m2 for women (Gomez-Ambrosi et al 2012). Evidence suggests 
that intra-abdominal visceral fat accumulation rather than BMI is related to the 
dysfunction of adipocytes and cardiometabolic disorders in obesity (Kishida et al 
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2011). Furthermore, findings from large prospective cohort studies show that the 
association of risk of cardiovascular disease and death with increasing waist 
circumference is stronger in non-obese compared with obese individuals (Stefan 
et al 2013). In 2008, WHO Expert Consultation published a report “Waist 
Circumference and Waist-Hip Ratio” which found that an increase of the waist 
circumference and the waist-hip ratio is associated with increased disease risk. 
These measures of abdominal obesity were correlated with BMI, but the level of 
associations varied, suggesting that these measures may provide different 
information and thus may not be interchangeable. However, further studies are 
needed to establish whether the recommended waist circumference cut-off points 
should be specific to sex, age and population (World Health Organization 2008). 
In patients with abdominal obesity, adipocytes are accumulated into two com-
partments: subcutaneous fat and visceral fat, the latter considered as being more 
pathogenic (He et al 2010). Although BMI may be below 25 kg/m2, visceral fat 
may be increased; thus measuring waist circumference becomes particularly 
important in people with lower BMI (Cheng 2004). Furthermore, waist circum-
ference does not precisely represent the entire abdominal fat compartments. 
Visceral fat obesity (defined as a visceral fat area of ≥100 cm2 measured by 
computer tomography (CT)) can occur in subjects with normal body weight and 
normal waist circumference. Therefore, exact assessment of abdominal adipose 
tissue requires more comprehensive technology, such as CT, magnet resonance 
imaging (MRI), and ultrasound (He et al 2010).  
 
 
4.1.2. Comparison of WHO and American Diabetes Association 
(ADA) definitions for impaired glucose regulation  
Definitions for impaired glucose regulation have been developed and agreed 
with both by WHO and ADA. Diabetes is a group of metabolic diseases charac-
terized by hyperglycaemia resulting from defects in insulin secretion, insulin 
action, or both. Diabetes classification involves four main types of diabetes: 
type 1, type 2, other specific types and gestational diabetes. Type 2 diabetes, 
which accounts for ~90–95% of those with diabetes, encompasses individuals 
who have insulin resistance and usually relative insulin deficiency. Type 1 dia-
betes accounts for only 5–10% of those with diabetes and results from a 
cellular-mediated autoimmune destruction of the β-cells of the pancreas (Ameri-
can Diabetes Association Position Statement 2013). The long-term relatively 
specific effects of diabetes include development of retinopathy, nephropathy 
and neuropathy. People with diabetes are also at increased risk of cardiac, 
peripheral arterial and cerebrovascular disease (World Health Organization 
2011). Diabetes and impaired glucose tolerance (IGT) are defined similarly by 
WHO and ADA. Both ADA and WHO agree that glycated haemoglobin 
(HbA1c) of 6.5% (48 mmol/mol) is recommended as the cut-off point for 
diagnosing diabetes and a value less than 6.5% (48 mmol/mol) does not exclude 
diabetes diagnosed by using glucose tests (World Health Organization 2011, 
International Expert Committee 2009) (Table 2). In contrast, the fasting plasma 
14 
glucose cut-off point for impaired fasting glucose (IFG) is 6.1 mmol/l according 
to the WHO criteria (World Health Organization 2006), but 5.6 mmol/l 
according to the ADA criteria (Genuth et al 2003) (Table 2). In Estonia, im-
paired glucose regulation is diagnosed according to the WHO criteria (Eesti 
Endokrinoloogia Selts, Eesti Perearstide Selts 2008) and a national guideline for 
using HbA1c to diagnose diabetes was published in 2012 (Rajasalu 2012). 
IFG and IGT represent metabolic states intermediate between normal 
glucose homeostasis and diabetic hyperglycaemia (Unwin et al 2002). The 
ADA classifies IFG, IGT and also HbA1c value in the range of 5.7–6.4% (39–
46 mmol/mol) as prediabetic conditions (American Diabetes Association Po-
sition Statement 2013). In contrast, WHO considers that there is currently in-
sufficient evidence to make any formal recommendation on the interpretation of 
HbA1c levels below 6.5% (48 mmol/mol) (World Health Organization 2011). 
The Estonian national guideline does not define prediabetes by HbA1c, but still 
recommends to perform an oral glucose tolerance test (OGTT) for subjects 
having HbA1c 6.0–6.4% (42–46 mmol/mol) (Rajasalu 2012). A recent meta-
analysis showed that IFG and IGT are associated with modest increase in the 
risk for cardiovascular disease (Ford et al 2010). Prediabetes often progresses to 
overt diabetes within a few years and may be associated with increased risk of 
microvascular and macrovascular complications (Moutzouri et al 2011).  
 
 
Table 2. Comparison of the WHO and ADA definitions of impaired glucose regulation  
 WHO 2011 ADA 2013 
Diabetes 
Fasting plasma glucose 
 






≥7.0 mmol/l  
or 




≥6.5% (≥48 mmol/mol) 
 
≥7.0 mmol/l  
or 
≥ 11.1 mmol/l  
or 
≥ 11.1 mmol/l  
or 
≥6.5% (≥48 mmol/mol) 
Impaired glucose tolerance (IGT) 
Fasting plasma glucose 
 
2-hour plasma glucose in OGTT 
 







Impaired fasting glucose (IFG) 
Fasting plasma glucose 
 









Fasting plasma glucose 
 










* in patients with classic symptoms of hyperglycaemia 
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4.1.3. Review of the definitions of metabolic syndrome 
Metabolic syndrome (MS) is a complex of interrelated risk factors for cardio-
vascular disease and diabetes (Alberti et al 2009). In 1988, Reaven defined 
syndrome X, a cluster of risk factors for coronary artery disease, which involved 
resistance to insulin stimulated glucose uptake, glucose intolerance, hyper-
insulinaemia, increased level of triglycerides, decreased level of high-density 
lipoprotein (HDL) cholesterol and hypertension (Reaven, 1988). Thereafter, 
various diagnostic criteria of MS have been proposed by different organizations. 
The first formal definition of the metabolic syndrome was published by the 
WHO in 1998 and this focused primarily on the presence of insulin resistance 
which was defined by hyperinsulinaemia, IGT or type 2 diabetes. In addition, 
two of the following criteria, dyslipidaemia, hypertension and microalbu-
minuria, also had to be present (Alberti et al 1998). Shortly thereafter (in 1999), 
an alternative definition of metabolic syndrome was proposed by the European 
Group for the Study of Insulin Resistance (EGIR). The metabolic syndrome was 
defined by the presence of insulin resistance or fasting hyperinsulinaemia plus 
two of the following criteria: fasting plasma glucose ≥6.1 (but non-diabetic), 
hypertension, dyslipidaemia and central obesity (Balkau et al 1999). In 2001, a 
new definition of metabolic syndrome was published by the National Choles-
terol Education Program Adult Treatment Panel III (NCEP ATP III), which 
defined metabolic syndrome as the presence of three or more of the following: 
abdominal adiposity, dyslipidaemia, elevated fasting glucose and elevated blood 
pressure (Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults, 2001). The NCEP ATP III definition differed from both 
the WHO and the EGIR definitions in that insulin resistance was not considered 
as a necessary diagnostic component (Kassi et al 2011). Most recent definitions 
include the NCEP ATP III criteria developed by the American Heart As-
sociation/National Heart, Lung, and Blood Institute (AHA/NHLBI) (Grundy et 
al 2005) and the International Diabetes Federation (IDF) criteria (Alberti et al 
2005). The IDF criteria involved population-specific waist circumference plus 
any two of the following: dyslipidemia, hypertension, fasting glucose 
≥5.6 mmol/l (Alberti et al 2005). The remaining four components of metabolic 
syndrome in the AHA/NHLBI definition were identical to those of the IDF, 
although abdominal obesity was defined differently. The IDF recommended that 
the threshold for waist circumference in Europeans should be 94 cm for men 
and 80 cm for women, while the AHA/NHLBI recommended cut-off points of 
102 and 88 cm, respectively (Kassi et al 2011). In 2009, a Joint Interim State-
ment, which represented the outcome of an attempt to unify the criteria of meta-
bolic syndrome by several major organizations, was published (Alberti et al 
2009). According to this statement, presence of any three of the following five 




Table 3. Joint Interim Statement criteria for the clinical diagnosis of metabolic syndrome 
Measure  Categorical cut points 
Elevated waist circumference Population- and country-specific definitions¹ 
AHA/NHLBI (ATP III) cut-off points: 
≥102 cm for males 
≥88 cm for females 
Elevated triglycerides or drug 
treatment for elevated 
triglucerides 
≥1.7 mmol/l 
Reduced HDL cholesterol or 
drug treatment for reduced 
HDL cholesterol 
<1.0 mmol/l for males 
<1.3 mmol/l for females 
Elevated blood pressure or 
antihypertensive drug 
treatment in a patient with a 
history of hypertension 
Systolic ≥ 130 and /or diastolic ≥ 85 mm Hg 
Elevated fasting glucose or 
drug treatment of elevated 
glucose 
≥5.6 mmol/l 
¹ It is recommended that the International Diabetes Federation (IDF) cut-off points 
should be used for non-Europeans and either the IDF or AHA/NHLBI cut-off points 
should be used for people of European origin until more data are available. 
 
 
4.2. Epidemiology of overweight and obesity,  
impaired glucose regulation and metabolic syndrome 
4.2.1. Prevalence of overweight and obesity 
The prevalence of overweight and obesity is increasing at an alarming rate in 
developed and developing countries throughout the world. Before 1980, obesity 
rates were generally below 10% worldwide, but since then, rates have doubled 
or tripled in many countries, an in almost half of the Organization for Economic 
Cooperation and Development (OECD) countries 50% or more of the popu-
lation is overweight (Sassi 2010). The health risks associated with obesity and 
overweight make it a particularly relevant public health challenge worldwide. 
Overall, 23.2% of the world’s adult population in 2005 were overweight (24.0% 
of men and 22.4% of women) and 9.8% were obese (7.7% of men and 11.9% of 
women) (Kelly et al 2008). In 2008, an estimated 1.46 billion adults worldwide 
had BMI of 25 kg/m2 or greater, of these 205 million men and 297 million 
women were obese. Worldwide, the age-standardised prevalence of obesity was 
9.8% for men and 13.8% for women in 2008, which was nearly twice the 
prevalence of 4.8% for men and 7.9% for women in 1980 (Finucane et al 2011). 
If the current trends continue, over 50% of adults in the United States will be 
obese by 2030. (Walley et al 2009). On the other hand, data from the National 
Health and Nutrition Examination Survey (NHANES) showed that 34.9% of 
adults in United States were obese in 2011–2012, while the overall prevalence 
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did not differ between men and women and the prevalence of obesity among 
adults did not change between 2009–2010 and 2011–2012 (Ogden et al 2013). 
The prevalence of obesity in Europe ranges between 10–25% for men and 10–
30% for women (Tsigos et al 2008). Rates of overweight and obesity have been 
increasing over the past three decades everywhere in the OECD countries and 
projections suggest that if recent trends continue over the next ten years, the 
pre-obesity (BMI 25–29.9 kg/m2) rates for the 15–74 age group will stabilise 
and may even shrink slightly in many countries, while obesity rates continue to 
rise (Sassi 2010). To date, the prevalence of obesity in Estonia has only been 
estimated from self-reported data from posted questionnaire surveys. In 2008, 
among subjects aged 16–64, it was just 17.5% for men and 18.0% for women 
(Tekkel et al 2009). According to the WHO data, the prevalence of overweight 
(BMI≥25) and obesity (BMI≥30) among Estonians aged ≥20 years in 2008 was 
estimated to be 53.7% and 20.6%, respectively (World Health Organization 
2011b). No population-based study using objective measurements of weight and 
height has been conducted in Estonia.  
 
  
4.2.2. Prevalence of impaired glucose regulation 
4.2.2.1. Prevalence of diabetes 
The prevalence of diabetes and impaired glucose regulation is rapidly increasing 
worldwide (Shaw et al 2010). Type 2 diabetes accounts for 90–95% and type 1 
diabetes accounts for only 5–10% of adults with diabetes (American Diabetes 
Association Position Statement 2013). Type 1 diabetes is the most common 
metabolic disease in childhood and the European region displays the highest 
prevalence of type 1 diabetes in children (International Diabetes Federation 
2013). In Estonian children aged 0–14.9 years, the age-standardized incidence 
rate of type 1 diabetes for the period between 1999 and 2006 was 17.2 (Teeäär 
et al 2010). According to the global report of 2010, the worldwide prevalence of 
diabetes among 20–79-year-old adults was estimated to be 6.4% (285 million), 
which is projected to rise 7.7% (439 million) by 2030. The estimates for both 
2010 and 2030 showed a slight gender difference in the number of people with 
diabetes (Shaw et al 2010). The prevalence of diabetes increases with age: 
pooled data from 13 European cohorts showed that the prevalence of diabetes 
was <10% in subjects younger than 60 years and between 10–20% at the age of 
60–79 years (DECODE Study Group 2003). According to the most recent 
global report (International Diabetes Federation 2013), the worldwide pre-
valence of diabetes among 20–79-year-old adults was estimated to be 8.3% (382 
million) in 2013, which is projected to rise to 10.1% (592 million) by 2035. 
Almost half of all adults with diabetes are between the ages of 40 and 59 years. 
The number of people with diabetes in Europe in 2013 was estimated to be 56.3 
million, or 8.5% of the adult population. The country with the highest pre-
valence (14.9%) is Turkey, followed by Montenegro, Macedonia, Serbia, and 
Bosnia and Herzegovina (International Diabetes Federation 2013). The latest 
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projections of diabetes prevalence are considerably higher than earlier pre-
dictions: in 2000 the worldwide prevalence of diabetes for all adults ≥20 years 
of age was estimated to be 2.8% (171 million), which was projected to rise 
4.4% (366 million) by 2030 (Wild et al 2004). The accuracy of global estimates 
is hampered by the shortage of data on the prevalence of diabetes in particular 
regions, including Eastern Europe (Wild et al 2004, Shaw et al 2010). For 
Estonia, so far, data has been extrapolated from Polish data of different sources 
(personal communication and (Szurkowska et al 2001) and the estimated 
prevalence was 4.4% for 2000 (Wild et al 2004) and 9.9% for 2010 (Shaw et al 
2010). The marked increase in this indicator is most probably attributable to 
different data sets used for extrapolation. A smaller study conducted in 2006 in 
one region of Estonia indicated that the prevalence of diabetes among Estonian 
adults might be as high as 8.7% (Rajasalu et al 2008). However, in the latest 
IDF Diabetes Atlas our population-based study (Eglit et al 2011) was used as 
one of the data sources and the national prevalence of diabetes in Estonia was 
estimated to be 7.7% (Intenational Diabetes Federation 2013).  
 
 
4.2.2.2. Prevalence of impaired fasting glucose (IFG) and  
impaired glucose tolerance (IGT) 
In the majority of populations studied, IGT is more prevalent than IFG, and 
there is a difference in the phenotype and gender distribution between these two 
categories. The IFG is significantly more common among men and IGT is 
slightly more common among women. The prevalence of IFG tends to plateau 
in middle age whereas the prevalence of IGT rises up old age (Unwin et al 
2002). According to the results of the NHANES conducted in 2005–2006 and 
including 1547 nondiabetic adults, the prevalence of both IFG and IGT was 
9.8% and the prevalence of IGT alone was 5.4% (Karve et al 2010). According 
to the most recent global report, in 2013 approximately 316 million (6.9%) in 
the age group 20–79 years had IGT, which can be projected to increase to 471 
million (8.0%) among the adult population by 2035 (International Diabetes 
Federation 2013). The majority of adults with IGT are under the age of 50, and 
if left untreated, are at a high risk of progressing to type 2 diabetes in later life 
(International Diabetes Federation 2013). 
 
 
4.2.3. Prevalence of metabolic syndrome 
The prevalence of MS is increasing globally, without any universal or gender-
specific differences (Cornier et al 2008). Comparison of prevalence data for 
different populations is difficult because many studies compare prevalence rates 
by using different criteria of the metabolic syndrome (Eckel et al 2005). How-
ever, no matter which criteria are used, the prevalence of metabolic syndrome is 
high and rising in all Western societies, probably as a result of the obesity 
epidemic (Kassi et al 2011). Among adults in the United States, the prevalence 
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of ATP III-defined MS increased from 23.7% in 1988–1992 to 34.6% in 1999–
2002 (Ford et al 2002, Ford 2005). While the prevalence of MS is lower in 
Northern and Mediterranean Europe, it is increasing in many less developed 
nations (Batsis et al 2007). The Diabetes Epidemiology Collaborative analysis 
of the Diagnostic criteria in Europe (DECODE) Study, including pooled data 
from nine European population-based cohorts, showed that the prevalence of 
metabolic syndrome was 32.2% and 28.5% for men and women, respectively 
(Qiao 2006). A very consistent finding across different ethnic groups indicates 
that the prevalence of metabolic syndrome is highly age-dependent (Eckel et al 
2005). The prevalence of the metabolic syndrome increases even more dra-
matically (compared with the increase with age) with increasing BMI. However, 
it should be noted that even lean individuals may develop metabolic syndrome, 
which demonstrates the complexity of its pathogenesis (Kassi et al 2011).  
The Estonian population has undergone a rapid transition towards a Western 
sedentary lifestyle over the last decades and the prevalence of metabolic synd-
rome has not been previously studied in Estonia. 
 
 
4.3. Adipose tissue distribution and functions 
Adipose tissue is a complex and highly active metabolic and endocrine organ 
and the traditional concept of adipose tissue as a passive reservoir for energy 
storage is no longer valid (Kershaw et al 2004). There are two types of adipose 
tissue depending on its cell structure, location, colour, vascularization and 
function: white adipose tissue and brown adipose tissue (Vazgues-Vela et al 
2008). Brown fat was once thought to have a functional role only in rodents and 
human infants; however, recent studies using 18F-labelled 2-deoxy-glucose  
positron emission tomography (PET) in combination with CT clearly de-
monstrated the presence of metabolically active brown fat in adult humans 
(Schulz et al 2013). The most common location of brown fat is the neck and the 
supraclavicular area (Paidisetty et al 2009). Brown adipose tissue uses energy to 
produce heat through non-shivering thermogenesis. Obese individuals have 
25% decreased activation of this tissue after cold exposure and women appear 
to have more active brown adipose tissue than men (Clement et al 2010). Like 
white adipose tissue, brown adipose tissue can affect whole-body metabolism 
and its activation might lead to new approaches to promoting weight loss and 
increasing insulin sensitivity (Hassan et al 2012).  
The functions of white adipose tissue can be classified in three aspects: first, 
it is related to lipid metabolism including triglycerides storage and fatty acids 
release; second, it catabolizes triglycerides in order to release glycerol and fatty 
acids that participate in glucose metabolism in the liver and other tissues and, 
third, it secretes adipokines (Vazgues-Vela et al 2008). Additionally, white adi-
pose tissue can act as a thermal insulator and protect other organs from mecha-
nical damage (Hassan et al 2012). In humans, adipose tissue is located beneath 
the skin (subcutaneous adipose tissue), around internal organs (visceral adipose 
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tissue), in bone marrow (yellow bone marrow), and in breast tissue (Hassan et al 
2012). Fat mass is dependent on both adipocyte cell number and size. The 
number of adipocytes is determined during early adulthood and changes in fat 
mass are attributed to changes in adipocyte cell size. Large adipocytes are more 
insulin-resistant and lipolytic, and release more inflammatory cytokines and less 
adiponectin (Gustafson 2010). Gender differences in deposition of body fat are 
evident even at the foetal stage. After adjusting for differences in height, men 
have higher total lean mass and bone mineral mass, and lower fat mass com-
pared with women. Also men have relatively higher central distribution of fat 
while women have a more peripheral distribution of fat (World Health Orga-
nization 2008). Visceral fat accounts for ~20% of total body fat in men com-
pared with only ~6% in pre-menopausal women (Gustafson 2010). However, 
pregnancy and menopause are associated with an increase in fat mass in 
women, and a redistribution of fat to the abdominal area (World Health Organi-
zation 2008). It has been speculated that the reduced tendency to accumulate fat 
within intraabdominal sites may be one of the primary metabolic differences 
underlying the reduced risk of cardiovascular disease, metabolic syndrome, and 
diabetes in women (Regitz-Zagrosek et al 2006). 
 
 
4.4. White adipose tissue as an endocrine organ 
White adipose tissue is an active endocrine organ that releases a large number 
of bioactive mediators (adipokines) modulating haemostasis, blood pressure, 
lipid and glucose metabolism, inflammation, and atherosclerosis (Rabe et al 
2008). White adipose tissue contains different cell types: one third of the tissue 
consists of adipocytes and the rest consists of fibroblasts, macrophages, stromal 
cells, monocytes and preadipocytes (Vazgues-Vela et al 2008). Mature adipo-
cytes are the main source of leptin and adiponectin; macrophages produce 
almost all tumour necrosis factor alpha (TNFα), resistin and visfatin, while 
prostaglandin E2, interleukins, vascular endothelial growth factor and hepato-
cyte growth factor are synthesized by stromal and vascular cells (Gnacinska et 
al 2009). Visceral adipose tissue secretes higher levels of complement factors, 
adiponectin, and inflammatory markers such as interleukin 6 (IL6), IL8, angio-
tensinogen and plasminogen activator inhibitor-1 (PAI-1), while abdominal 
subcutaneous fat is probably the main source of increased levels of circulating 
free fatty acids (FFA) (Gustafson 2010). So far as many as 100 substances 
synthesized by white adipose tissue have been discovered (Gnacinska et al 
2009). Among these, adiponectin and leptin are the most abundant adipocyto-
kines produced by adipocytes (Tilg et al 2006) and adiponectin has gained con-
siderable attention because of its antidiabetic, antiatherogenic and anti-inflam-
matory properties; furthermore, it has an important protective role in carcino-




4.5. Obesity and metabolic syndrome:  
pathogenesis (focused on adipose tissue dysfunction) and 
clinical significance 
4.5.1. Obesity 
4.5.1.1. Factors associated with development of obesity 
The accumulation of body fat in obese people indicates the failure of the body`s 
systems to ensure proper energy homeostasis by adjusting for environmental 
influences, behaviour, psychological factors, genetic make-up and neurohormo-
nal status (Clement et al 2010). The Big Two explanations proffered for the 
obesity epidemic are reduced physical activity and specific food manufacturing 
and marketing practices (Keith et al 2006). It is clear that through “over-
nutrition”, glucose, lipids and endotoxin can affect different tissues to mediate 
an aberrant inflammatory response and advance the pathogenesis of insulin 
resistance and metabolic disease; therefore, dysfunctional diets might provide 
the key targets for intervention (Piya et al 2013). However, there are several 
other additional putative contributors which might explain the increase of 
obesity: sleep deprivation, endocrine disruptors, reduction in variability in am-
bient temperature, decreased smoking, pharmaceutical iatrogenesis, changes in 
distribution of ethnicity and age, increasing gravid age, intrauteral and inter-
generational effects. Higher BMI is associated with better reproductive fitness-
yielding selection for obesity-predisposing genotypes and assortative mating 
(Keith et al 2006). In addition, studies have suggested that disruption of the 
circadian system or chronodisruption (shift work, sleep deprivation and expo-
sure to bright light at night) may also lead to obesity (Garaulet et al 2010). A 
novel factor identified to have a role in human obesity and associated metabolic 
risks is the commensal microbiota of the intestine or the gut microbiota (Cle-
ment 2011). There is also growing evidence about the link between obesity and 
low circulating 25-hydroxyvitamin D concentrations, but the cause-effect 
relationship remains unclear in this case (Earthman et al 2012). According to 
the thrifty genotype hypothesis, the high prevalence of type 2 diabetes and obe-
sity is a consequence of genetic variants that have undergone positive selection 
during historical periods of erratic food supply. However, no consistent pattern 
of selection that could provide conclusive confirmation of the thrifty genotype 
hypothesis was found by Southam et al who analysed 17 loci of type 2 diabetes 
and 13 loci of obesity (Southam et al 2009). In conclusion, it is clear that the 
worldwide epidemic of obesity is not of genetic origin but is due to changes in 
the lifestyle and environment. However, it is also clear that genetic factors 
greatly influence who gains weight as well as the magnitude of weight gain, 
placing individuals in the same “obesogenic” environment at significantly diffe-




4.5.1.2. Adipose tissue dysfunction in obesity 
Obesity is characterized by increased storage of fatty acids in an expanded 
adipose tissue mass and altered adipokine production, which is closely associated 
with the development of insulin resistance in peripheral tissues such as skeletal 
muscle and the liver (Figure 1) (Galic et al 2010). Excessive adipose tissue can 
contribute to inflammation in two ways: ectopic fat storage induces lipotoxicity, 
promoting an intracellular inflammatory response, and altered adipokine pro-
duction in obesity contributes to the inflammatory response. Adiponectin has a 
role in both of these processes (Whitehead et al 2006). It is well established that 
where there is an expansion of adipose tissue, such as that observed in obesity, 
there is a sustained inflammatory response accompanied by adipokine dysregu-
lation, which leads to chronic subclinical inflammation as well as insulin resis-
tance. While adipose tissue from lean individuals may preferentially secrete anti-
inflammatory adipokines such as adiponectin, transforming growth factor β 
(TGFβ), IL10, IL4, IL13 and apelin, then in obesity there are released pro-inflam-
matory adipocytokines such as TNFα, IL6, leptin, visfatin, resistin, angiotensin II 
and PAI-1, as well as several interleukins coupled with a reduction in secretion of 
anti-inflammatory adipokines (Piya et al 2013).  
Adipokines, such as adiponectin, leptin, resistin and visfatin, provide an im-
portant link between obesity, insulin resistance, and related inflammatory dis-
orders (Tilg et al 2006). The functionality of white adipose tissue cells involves 
the integration of several biochemical pathways: lipogenesis, lipolysis and fatty 
acids oxidation. Maintenance of equilibrium of these pathways under different 
metabolic conditions depends on the regulation of expression of genes, on the 
capacity of adipocytes to respond to external signals generated by hormones 
(insulin, glucagon) and by the same adipocytes or by the cells surrounding the 
adipocytes (macrophages) and a secretion of several adipokines by functional 
adipocytes (Vazgues-Vela et al 2008).  
The key abnormalities that occur in the adipose tissue of 75% of severely 
obese people who are insulin resistant (approximately 25% are insulin sensitive) 
are impaired triglyceride storage and increased lipolysis by lipid droplets, mito-
chondrial dysfunction, inflammation, and increased oxidative and endoplasmic 
reticulum stress. Increased release of free fatty acids, reactive oxygen species, 
and inflammatory cytokines and decreased release of adiponectin from the 
adipocyte are thought to act on peripheral tissues causing such disorders as type 
2 diabetes, atherosclerosis and non-alcoholic fatty liver disease. (Xu et al 2013). 
The underlying mechanism responsible for hypoadiponectinemia in the obese 
state is obscure. In obesity, increased fat mass results in hypoxia of adipose 
tissue, which increases endoplasmic reticulum stress (Su et al 2011). Auto-
phagy, induced by endoplasmic reticulum stress, is an important mechanism 
underlying obesity-induced adiponectin downregulation in adipocytes (Zhou et 
al 2010). Obesity also induces macrophage filtration into adipocytes, resulting 
in a low-grade chronic inflammatory state accompanied by increased production 
of pro-inflammatory cytokines, such as TNFα, IL6 and IL8, which in turn can 
suppress adiponectin mRNA levels and its secretion from adipocytes (Su et al 
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2011). The BMI, the waist and hip circumference, the waist-to-hip ratio and 
intra-abdominal fat are inversely correlated with plasma adiponectin, with the 






Figure 1. Obesity-induced changes in adipokine secretion and development of insulin 
resistance (Galic et al 2010) 
Expansion of adipose tissue in obesity leads to increased macrophage infiltration and in-
flammation with enhanced production of pro-inflammatory cytokines such as TNFα and 
IL6. This is accompanied by an increased release of free fatty acids and dysregulated 
secretion of leptin, adiponectin, resistin and retinol binding protein-4 (RBP4). Together, 
these adipocyte- and macrophage-derived substances can act in a paracrine or autocrine 
fashion to further exacerbate adipose tissue inflammation. On the systemic level, altered 
adipokine secretion can lead to increased food intake and reduced energy expenditure 
through actions in the hypothalamus and to decreased muscle and liver insulin sensiti-






4.5.1.3. Clinical significance of obesity 
The risk of hypertension is up to five times higher among obese people than 
among those with normal weight. Coronary heart disease risk increases with 
low concentrations of HDL, as well as with high concentrations of triglycerides. 
The relationship between obesity and type 2 diabetes is so strong that Sims et al 
coined the term “diabesity” in the 1970s (Haslam et al 2005). Other consequen-
ces of obesity include heart failure, endocrine disorders (hyperandrogenaemia, 
polycystic ovary syndrome), obstructive sleep apnoea, respiratory failure, 
asthma, cholelithiasis, osteoarticular diseases, fatty liver, gastroesophageal 
reflux disease and psychological disorders such as depression. Obesity is also a 
risk factor for several malignant tumours, with cancers of the prostate, gall-
bladder, kidney and pancreas commonly affecting men and tumours of the 
endometrium, cervix, ovary, breast and large intestine being more prevalent in 
women (Gnacinska et al 2009). Obesity has been shown to decrease life ex-
pectancy by 7 years at the age of 40 years (Haslam et al 2005). The relationship 
between BMI and mortality can generally be illustrated by a U-shaped curve 
with increased mortality both in the case of lower and higher values. The causes 
of overweight and obesity-related increased mortality include cardiovascular 
disease, diabetes and kidney disease, and obesity related cancers (Dixon 2010). 
  
 
4.5.1.4. Metabolically healthy obese phenotype 
Being overweight or obese causes and exacerbates a large number of health 
problems, both independently and in association with other risk factors and di-
seases (Kopelman 2007). 
Interestingly, not all obese individuals develop metabolic and cardiovascular 
disorders associated with obesity. It has been hypothesized that this is due to the 
preservation of normal adipose tissue architecture and function (Bluher 2009). 
Approximately 25% of severely obese individuals are insulin sensitive, as 
assessed by hyperinsulinemic-euglycemic clamps or by a homeostasis model of 
assessment (HOMA). Studies of bariatric surgery have shown that these indi-
viduals have higher levels of adenosine monophosphate-activated protein kinase 
(AMPK) and lipid droplet protein expression in adipose tissue, less oxidative 
stress in all of their fat depots and a decreased expression of several inflam-
matory genes (TNFα, interferon gamma (IFNγ), cluster of differentiation 4 
(CD4)), which is more depot-selective (Xu et al 2012, Xu et al 2013).  
While there exists no uniform definition of any phenotypical subtypes of 
obesity, the term “metabolically normal obesity” describes the absence of any 
overt cardiometabolic disease. In addition, the components of metabolic synd-
rome or inflammatory markers have also been used in categorizing subjects as 
metabolically normal or abnormal (Pataky et al 2010). Compared with normal 
weight individuals, mortality risk is increased in metabolically unhealthy obese 
individuals but not in metabolically healthy obese subjects, if metabolic health is 
defined by the homeostasis model assessment of insulin resistance (HOMA-IR) 
(Durward et al 2012, Hinnouho et al 2013). On the other hand, other studies have 
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reported similarly increased mortality risk for both metabolically healthy and 
unhealthy obese subjects (Stefan et al 2013). Factors that might distinguish meta-
bolically healthy but obese individuals and metabolically abnormal obese subjects 
despite their similar fat mass are: insulin sensitivity, amount of ectopic fat, tri-
glycerides level, HDL-cholesterol level, inflammation level, intima-media thick-
ness, adiponectin level and apolipoprotein B (ApoB) level (Primeau et al 2011). 
Metabolically healthy obese subjects have more subcutaneous but less visceral fat 
mass, and lower ectopic fat deposition in the liver and in the skeletal muscle 
compared with metabolically unhealthy obese individuals (Stefan et al 2013). The 
metabolically healthy obese phenotype is characterized, besides other factors, by 
adiponectin levels similar to those in subjects with normal body weight (Aguilar-
Salinas et al 2008, Doumatey et al 2012). Adiponectin regulates the expansion of 
subcutaneous adipose tissue and reduced storage of lipids in the liver, both of 
which being important determinants of insulin sensitivity (Stefan et al 213). Data 
about HMW adiponectin levels in the metabolically healthy obese phenotype is 
scarce. To the best of our knowledge, the only few studies have been conducted 
on women, where serum HMW adiponectin levels have been investigated in 
obese but metabolically healthy women (Bik et al 2010, Elisha et al 2010).  
 
 
4.5.2. Metabolic syndrome 
4.5.2.1. Factors involved in the pathogenesis of metabolic syndrome 
Although obesity and insulin resistance appear to be at the core in the patho-
physiology of metabolic syndrome, a number of other factors such as chronic 
stress, increased cellular oxidative stress, chronic activation of the immune 
system, activity of the renin-angiotensin-aldosterone system, microRNA-s, pre-
natal and early-life influences, multiple gene combinations and the contributions 
of cytokines, hormones and other molecules produced by adipocytes can also be 
involved in its pathogenesis (Simmons et al 2010, Kassi et al 2011, Hutcheson 
et al 2012). On the other hand, considering the data that 20% of morbidly obese 
individuals are metabolically healthy, and up to 40% of adults with normal 
weight have metabolic disorders typically associated with obesity (hyper-
tension, dyslipidaemia, non-alcoholic fatty liver disease, type 2 diabetes), it 
might be assumed that obesity may not be a primary cause of metabolic synd-
rome but it may be rather another marker for the underlying metabolic dys-
function that potentially drives its development (Weiss et al 2013).  
 
 
4.5.2.2 Insulin resistance and adipose tissue dysfunction  
in metabolic syndrome 
The most widely accepted hypothesis to describe the pathophysiology of the 
metabolic syndrome is insulin resistance, however, it remains unclear whether 
this is a unifying pathophysiological mechanism (Eckel et al 2005, Cornier et al 
2008). The pathophysiology of metabolic syndrome, characterized by abdominal 
obesity, insulin resistance and adipose tissue dysfunction, is shown in Figure 2
26
 
   










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Eckel et al 2005). Insulin resistance in the liver, muscle, and adipose tissue is 
not only associated with the abundance of proinflammatory cytokines and 
relative deficiency of the anti-inflammatory cytokine adiponectin, but is a direct 
result of this burden (Eckel et al 2005). A strong and consistent inverse asso-
ciation between adiponectin and insulin resistance and inflammatory states has 
been established, and conversely, adiponectin levels increase when insulin 
sensitivity improves (after weight reduction or treatment with insulin-sen-
sitizing drugs) (Kershaw et al 2004). Several studies have demonstrated that 
decreased level of adiponectin is a reliable biomarker for metabolic syndrome 
(Brochu-Gaudreau et al 2010) as well as an independent risk factor for non-
alcoholic fatty liver disease (NAFLD) (Wang et al 2009). Furthermore, hypo-
adiponectinaemia is highly associated with the development of insulin resis-
tance and type 2 diabetes (Borchu-Gaudreau et al 2010) and may be causally 
related to metabolic syndrome (Kassi et al 2011). On the other hand, the 
relationship between adiponectin and insulin action in humans is more complex 
than often suggested and there might be a bidirectional relationship between 
insulin resistance and hypoadiponectinaemia in humans (Cook et al 2010). 
 
 
4.5.2.3. Clinical significance of metabolic syndrome 
Individuals affected by MS have at least a fivefold increased risk of type 2 
diabetes and a twofold increased risk of cardiovascular disease, the latter being 
independent of other classical risk factors, such as high low-density lipoprotein 
(LDL) cholesterol and smoking (Eckel et al 2005, Mottillo et al 2010). A meta-
analysis showed that the point estimates of metabolic syndrome for cardio-
vascular risk were consistently higher in women vs. men (Tenenbaum et al 
2011). In addition to increased risk for cardiovascular disease and type 2 dia-
betes, metabolic syndrome is associated with a number of other clinical condi-
tions: NAFLD, polycystic ovary syndrome (PCOS), obstructive sleep apnoea, 
hypogonadism, microvascular disease, prothrombotic state, proinflammatory 
state (Cornier et al 2008) and certain forms of cancer (Braun et al 2011). A 
recent metaanalysis showed that the presence of metabolic syndrome was as-
sociated with liver, colorectal, and bladder cancer in men and with endometrial, 
pancreatic, breast postmenopausal, rectal, and colorectal cancer in women 
(Esposito et al 2012). 
Metabolic syndrome may be present in a wide range of groups, from appa-
rently healthy younger individuals, to older individuals with advanced stages of 
cardiovascular disease. The practical utility of MS has been greatly challenged 
during recent years (Borch-Johnsen et al 2010, Simmons et al 2010, Kahn et al 
2005, Kahn 2008). The following concerns have been raised by critics of the 
concept: no unifying pathophysiological mechanism of MS has been identified 
as yet; the risk of cardiovascular disease conferred by the syndrome appears no 
greater than the sum of its parts; and the rationale for the thresholds of various 
diagnostic criteria is still poorly defined (Kahn et al 2005). Another short-
coming has been inclusion of individuals with established diabetes and heart 
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disease (Simmons et al 2010). However, it is still widely recognised that beyond 
age, high LDL cholesterol and other standard risk factors, MS helps identify 
residual vascular risk associated with insulin resistance and atherogenic dysli-
pidaemia (low HDL cholesterol, high triglycerides, small dense LDL choleste-
rol) (Tenenbaum et al 2011, Cameron et al 2009). There is general agreement 
that MS denotes a high life-time risk of diabetes and cardiovascular disease and 
it has been proposed that after exclusion of individuals with established diabetes 
and cardiovascular disease, MS should be considered a pre-morbid condition 
(Simmons et al 2010).  
Metabolic syndrome is a strong risk factor for the development of cardio-
vascular disease in general and occlusive coronary artery disease in particular, 
and confers greater risk than the sum of its individual components, but the 
contribution of each component remains a matter of debate and might be 




4.6.1. Adiponectin synthesis, secretion and actions 
Human adiponectin is a 244aminoacid/30kilodaltons protein encoded by a 
single gene transcript on chromosome 3q27.3 which is considered a suscepti-
bility locus of type 2 diabetes and metabolic syndrome (Simpson et al 2010, 
Maeda et al 2013). Adiponectin accounts for approximately 0.01% of total 
plasma protein with plasma levels in the µg/ml range, around three orders of 
magnitude higher than leptin (Whitehead et al 2006). Adiponectin is synthe-
sized by adipocytes as a single subunit which undergoes multimerisation to 
form low-molecular-weight (LMW) (trimers and hexames) and HMW (12–18-
mers) multimers prior to secretion and exerts its biological effects mainly 
through its receptors, adiponectin receptor 1 (AdipoR1) and AdipoR2 (Anto-
niades et al 2009, Simpson et al 2010). The AdipoR1 is expressed ubiquiously, 
whereas AdipoR2 is expressed most abundantly in the liver (Rabe et al 2008). 
In addition to AdipoR1 and AdipoR2, the cell-surface glycoprotein T-cadherin 
has been identified as a receptor required for conferring the cardio-protective 
effects of adiponectin (Hui et al 2012). In plasma, adiponectin circulates as a 
LMW trimer, a middle-molecular-weight (MMW) hexamer, and HMW 12- to 
18-mer, which have different target tissues and/or differing biological effects 
(Wang et al 2008, Rabe et al 2008, Simpson et al 2010). The physiological 
function of adiponectin has been clarified and mainly investigated by using 
adiponectin knockout (Adipo-KO) mice (Maeda et al 2013). Activation of 
AMPK is the central mechanism of the biological effects of adiponectin (Shetty 
et al 2009, Wang et al 2008). The AdipoR1 and AdipoR2 also mediate 
adiponectin-evoked activation of peroxisome-proliferator activated receptor 
alpha (PPARα) and P38 mitogen-activated protein (MAP) kinase in the liver, 
sceletal muscle and endothelial cells (Hui et al 2012). Adiponectin has anti-
inflammatory actions in a variety of tissues: direct effects on monocyte/ 
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macrophages, endothelial cells, hepatic and muscle cells plus indirect effects via 
inhibition of TNFα production and action (Whitehead et al 2006) and sup-
pression of IL6 expression (Rabe et al 2008). Adiponectin increases nitric oxide 
(NO) production and/or ameliorates oxidized LDL (oxLDL)-induced suppres-
sion of endothelial NO synthase (eNOS) activity, and loss of adiponectin is 
associated with impaired endothelium-dependent vasorelaxation. Adiponectin 
also inhibits one of the initial steps in atherogenesis, i.e. TNFα-stimulated 
adherence of monocytes to cultured human endothelial cells, and affects plaque 
formation and stability (Matsuzawa 2005). Adiponectin regulates glucose 
homeostasis through suppression of hepatic gluconeogenesis, stimulation of 
fatty acid oxidation in the liver and skeletal muscle and glucose uptake in 
skeletal muscle, stimulation of insulin secretion and modulation of food intake 
and energy expenditure (Rabe et al 2008). Adiponectin is considered to have 
anticarcinogenic effects, being a negative regulator of angiogenesis and having 
anti-inflammatory properties (Braun et al 2011). Recent studies also indicate 
that adiponectin is directly involved in bone-mass regulation, revealing both 
positive and negative correlations (Shetty et al 2009). The actions of adipo-
nectin in major target tissues are shown in Figure 3 (Simpson et al 2010).  
Numerous studies have indicated that the HMW form of adiponectin is its 
most active form (Hara et al 2006, Hajer et al 2008, Mattu et al 2013) which 
also mediates the insulin-sensitizing and cardiovascular protective effects of 
adiponectin (Hui et al 2012). Due to its anti-inflammatory, anti-atherogenic, 
anti-diabetic and cardioprotective effects and promotion of efficient endothelial 
function, adiponectin is termed as “beneficial” adipocytokine (Mattu et al 
2013).  
Both genetic and environmental factors affect circulating adiponectin levels 
(Kishida et al 2011). Single nucleotide polymorphisms (SNPs) present in the 
adiponectin gene are independently associated with one or more aspects of 
metabolic syndrome, including type 2 diabetes, increased BMI, waist circum-
ference, dyslipidaemia, altered blood pressure and coronary artery diseases 
(Shetty et al 2009, Su et al 2011 ). Adiponectin gene transcription is upregulated 
by peroxisome proliferator activator receptor gamma (PPARγ) and down-
regulated in the adverse environment of chronic low-grade inflammation, 
oxidative stress, and endoplasmic reticulum stress that is associated with obesity 
(Phillips et al 2010). Many existing drugs have been found to increase adipo-
nectin levels, such as thiazolidinediones, statins, angiotensin converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs), fenofibrate, niacin, 
acarbose, glimepiride, androgen blockers and rimonabant (withdrawn from the 
market due to psychiatric side effects) (Phillips et al 2010). Adiponectin levels 
are also hormonally regulated: testosterone selectively decreases the circulating 
levels of HMW adiponectin, triggering lower levels of adiponectin in men 
compared to women (Wang et al 2008, Shetty et al 2009). There are also ethnic 
differences in adiponectin levels: plasma total and HMW adiponectin con-
centrations were lower in Chinese and South Asians compared with Canadian 
aborigines and Europeans (Sulistyoningrum et al 2013). 
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Figure 3. Actions of adiponectin in major target tissues.  
NAFLD: non-alcoholic liver disease; NASH: non-alcoholic steatohepatitis. 
 
 
In obese subjects, weight loss and increased physical activity are associated 
with an increase in plasma adiponectin (Matsuzawa 2005). Specifically, a net 
weight loss larger than 10% of initial body weight seemed necessary for long-
term combined improvement of adiponectin, high sensitive-C reactive protein and 
fibrinogen levels (Madsen et al 2008). Marked elevation of adiponectin is seen in 
humans in chronic calorie deficiency (anorexia nervosa) (Cook et al 2010).  
In conclusion, low adiponectin level is a biomarker of a number of disease 
conditions (obesity, insulin resistance and type 2 diabetes, cardiovascular di-
seases, dyslipidaemia, hypertension, metabolic syndrome). At the same time, 
adiponectin itself mediates a range of anti-inflammatory, anti-atherosclerotic 
and antidiabetic effects, therefore being closely involved in the pathogenesis of 
diabetes and cardiovascular diseases (Matsuzawa 2005, Su et al 2011). In ad-
dition, adiponectin may provide a mechanism by which obesity and insulin 
resistance are causally associated with cancer risk and its poor prognosis (Mat-
suzawa 2005).  
 
 
4.6.2. Gender difference in adiponectin levels 
Previous studies have convincingly shown that males have significantly lower 
levels of adiponectin than females (Nishizawa et al 2002, Rathmann et al 2007, 
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Wang et al 2008, Ahonen et al 2009). Xu et al have found that the concentration 
of HMW adiponectin in females was significantly higher than that in males, 
whereas there were no gender difference for the other two forms. Therefore, 
selective inhibition of HMW adiponectin by testosterone might contribute to the 
sex dimorphism of adiponectin levels and could partly explain why men have 
higher risk for insulin resistance and atherosclerosis than women (Xu et al 
2005). Several lines of evidence suggest that both androgens and oestrogens 
play negative roles in the production of adiponectin. Neonatal castration of male 
rats results in adiponectin levels similar to those observed in females and 
ovariectomy in adult women also increases circulating adiponectin levels 
(Whitehead et al 2006). 
 
 
4.6.3. Adiponectin, inflammation and metabolic risk factors: 
consensus and controversy 
Among various adipokines, adiponectin stands out due to its abundant expres-
sion in adipose tissue and inverse relationship with insulin resistance (Rabe et al 
2008), metabolic syndrome (Rabe et al 2008, Hirose et al 2010) and type 2 
diabetes (Snijder et al 2006, Jalovaara et al 2008, Rabe et al 2008, Cook et al 
2010, Zhu et al 2010). Serum HMW adiponectin values are inversely correlated 
with presence of metabolic syndrome in both genders (Hara et al 2006, Eglit et 
al 2013). The HMW adiponectin is the most active form of the hormone, and 
has a better predictive power compared to total adiponectin for glucose intole-
rance, insulin resistance and MS (Fisher et al 2005, Hara et al 2006, Rabe et al 
2008, Cook et al 2010). The HMW adiponectin is inversely associated with 
triglycerides, obesity and fasting glucose, and positively associated with HDL 
cholesterol (Liu et al 2007, Tabara et al 2008, Kawamoto et al 2011, Yu et al 
2011). The relationship between HMW adiponectin and blood pressure has 
varied between different studies as well as between the genders (Liu et al 2007, 
Tabara et al 2008, Kawamoto et al 2011b, Yu et al 2011). This calls for more 
detailed subtype analyses of the association between adiponectin, gender and 
metabolic risk factors.                                             
The most recent studies about associations between HMW adiponectin and 
MS come mainly from Asia (Liu et al 2007, Lee et al 2009, Kawamoto et al 
2011, Yu et al 2011) and from the United States (Devaraj et al 2008). The 
SWAN study from the United States showed significant racial-ethnic diffe-
rences in circulating adipokine levels. Women of Caucasian origin had higher 
levels of total and HMW adiponectin compared with women of African 
American, Chinese and Japanese origin (Khan et al 2012). Furthermore, the 
relationship between plasma HMW adiponectin and HOMA-IR is influenced by 
ethnicity to a greater degree for Chinese and South Asians compared with 
Europeans (Sulistyoningrum et al 2013). However, no data is available about 
associations between HMW adiponectin and metabolic syndrome in Europe. 
There is a clear gender difference in HMW adiponectin levels: women have 
significantly higher HMW adiponectin levels compared with men (Nishizawa et 
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al 2002). However, data about whether this gender dimorphism has any con-
sequences in cardiometabolic conditions in females versus males is scanty. A 
recent study from Finland investigating subjects with both metabolic syndrome 
and elevated blood pressure showed that absolute differences in total adipo-
nectin levels between subjects with and without metabolic syndrome were 
greater for women than for men (Ahonen et al 2009). Several studies have 
shown that the inflammation characterized by elevated C-reactive protein 
(CRP), predicted development of metabolic syndrome more accurately in 
women than in men. Furthermore, the association between elevated CRP and 
cardiovascular events was stronger for women than for men and the increase in 
cardiovascular risk accompanied by the appearance of diabetes was relatively 
greater for women than for men as reported in several studies (Regitz-Zagrosek 
et al 2006). In pharmacologically untreated subjects, the leptin/adiponectin ratio 
is the main factor associated with metabolic syndrome in men, while adipo-
nectin alone appears to be a protective factor in women (Cicero et al 2011). The 
Dutch Hoorn Study demonstrated that the relationship of high total adiponectin 
level with lower risk of impaired glucose metabolism and type 2 diabetes was 
stronger among women than among men in a group of 50–70-years-old subjects 
(Snijder et al 2006). However, no gender difference was found in associations 
between total adiponectin and cardiovascular risk factors in German subjects 
aged 55–74 years (Cooperative Health Research in the Region of Augsburg 
(KORA) Survey 2000) (Rathmann et al 2007). In subjects with a normal waist 
circumference, the prevalence of visceral fat obesity (defined as the area of 
visceral adipose tissue larger than 100 cm2 by CT) is lower and the expression 
of adiponectin and its receptor is higher in female subjects compared with male 
subjects (He et al 2010). Whether the higher expression of adiponectin and its 
receptor constitutes a mechanism for protecting female subjects from deve-
loping visceral fat obesity requires further investigation (He et al 2010).  
Controversial issues. A substantial amount of coherent data has generated 
the following paradigm: obesity is associated with inflammation in adipose 
tissue, proinflammatory factors suppress adiponectin production, low levels of 
adiponectin increase insulin resistance and risk of cardiovascular disease and 
low levels of adiponectin promote inflammation, thus generating a self-
sustaining inflammatory loop (Fantuzzi 2008). On the other hand, adiponectin 
levels have recently been shown to be increased in many chronic inflammatory 
and autoimmune diseases such as type 1 diabetes, systemic lupus erythema-
tosus, rheumatoid arthritis, inflammatory bowel disease, chronic systolic heart 
failure (contrary to the decrease in adiponectin levels in obesity related heart 
failure) and hypertrophic cardiomyopathy associated with diastolic dysfunction 
(Aprahamian et al 2011). This data might suggest that the paradigm “inflam-
mationlow adiponectinmore inflammation”, currently accepted in the 
context of obesity, metabolic syndrome, type 2 diabetes and cardiovascular 
disease, does not apply to classic chronic inflammatory conditions, in which 
increased adipose tissue mass does not likely play a pathogenic role (Fantuzzi 
2008). High adiponectin levels correlating with increased mortality in patients 
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with heart failure might be an expression of protective counter-regulatory 
measure to prevent further damage (Shetty et al 2009). Another opinion is that 
in severe heart failure elevated levels of adiponectin may just reflect the hyper-
catabolic state and therefore adiponectin levels are increased in heart failure 
only in the presence of cachexia (Antoniades et al 2009). In addition, adipo-
nectin concentration correlates positively with renal dysfunction, but it is 
unclear whether increased adiponectin levels in such a situation have a causa-
tive or reactive (and protective) role (Shetty et al 2009). More research into the 
role and regulation of adiponectin in inflammation and autoimmunity is clearly 







5. STUDY RATIONALE 
The prevalences of diabetes, impaired glucose regulation and metabolic syndro-
me have not been previously studied in Estonia. The prevalence of obesity has 
been estimated on the basis of self-reported data obtained by using a postal 
questionnaire survey, and no population-based study has been conducted. Data 
on gender-specific associations between adiponectin (especially HMW adipo-
nectin) levels and cardiometabolic risk factors is so far rather limited. Data 
























6. AIMS OF THE STUDY 
1. To estimate the prevalence of obesity, impaired glucose regulation and meta-
bolic syndrome in Estonian adult population. 
2.  To analyse associations between metabolic syndrome and insulin resistance. 
3.  To describe gender-specific associations between metabolic syndrome and 
HMW adiponectin level. 
4.  To analyse gender-specific associations between HMW adiponectin level 
and metabolic risk factors. 





































7. SUBJECTS AND METHODS 
A population-based, cross-sectional, multicentre study was conducted between 
November 2008 and May 2009 in three different counties (Viljandi, Põlva and 
Tartu) of Estonia. The study population consisted of randomly selected adults, 
aged 20 to 74 years, from four general practices (2 from the Viljandi County). 
The study participants were representative of the general Estonian population in 
terms of age and gender. An invitation letter about the study was sent to each 
participant. The total response rate was 53.2 percent, resulting in a total study 
population of 495 subjects (Table 1). 
 
 
Table 1.The age- and gender specific structure of the study population  
Age-group (years) Men (n) Women (n) Total (n) 
20–44  105 116 221 
45–60    64   99 163 
61–74    45   66 111 
Total  214 281 495 
 
 
On the day of the study, subjects visited their general practitioners (GPs) in the 
morning between 8 a.m. and 11 a.m. after an overnight fast (lasting at least 10 
hours). An informed consent form was signed, and blood pressure, waist 
circumference, height and weight were measured in participants wearing their 
indoor clothes without shoes. Blood pressure was measured using a mercury 
sphygmomanometer after the patient had been sitting for at least five minutes. 
The mean of three consecutive measurements was used for analysis, with at 
least a three-minute interval between each measurement. A face-to-face clinical 
interview was conducted to assess the presence of other medical conditions and 
cardiovascular risk factors. A standard OGTT (WHO 1999) was conducted with 
Glycodyn® solution (Biofile Ltd, Turku, Finland), except for the subjects with 
known diabetes mellitus. Plasma glucose was measured by the hexokinase 
method. Total cholesterol, HDL cholesterol, and triglycerides were measured 
using an enzymatic colorimetric assay (COBAS INTEGRA 800 plus ana-
lyzer, Roche, Basel, Switzerland). Plasma insulin was measured using a 
chemiluminescent assay (Immulite 2000 analyser, Siemens Healthcare 
Diagnostics, Deerfield, IL, USA). Plasma fasting HMW adiponectin was mea-
sured subsequently in 458 subjects (191 men) from plasma samples that had 
been stored at -80Cº for a maximum of 2.5 years and had never been thawed. 
The HMW adiponectin was detected by an Adiponectin (Multimetric) enzyme-
linked immunosorbent assay (ELISA) (ALPCO Diagnostics, Salem, NH, USA), 
using an automatic ELISA Triturus analyser (Grifols International, Barce-
lona, Spain). The intra-assay coefficient of variation for the HMW adiponectin 
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ELISA was 4.8 percent (n=9), and the interassay coefficient of variation was 6.9 
percent (n=7).  
The subjects were categorized as normal weight (BMI 18.5–24.9 kg/m2), 
overweight (BMI≥25.0 kg/m2) and obese (BMI ≥30.0 kg/m2) (World Health 
Organization 2000). Impaired glucose regulation was diagnosed according to 
the WHO criteria (World Health Organization 2006). Insulin resistance (IR) 
was estimated using homeostasis model assessment: HOMA-IR = fasting glu-
cose (mmol/l) x fasting insulin (mU/l)/22.5 (Wallace et al 2004). The IR was 
defined as the upper quartile of HOMA-IR for the whole study group 
(exempting subjects with previously known diabetes mellitus). The threshold 
for the whole study group was 1.92 (2.04 and 1.82 for men and women, respec-
tively).  
Metabolic syndrome was diagnosed on the basis of at least three of the follo-
wing NCEP ATP III criteria (Grundy et al 2005): waist circumference ≥102 cm 
in men and ≥88 cm in women, blood pressure ≥130/85 mmHg or taking anti-
hypertensive medication, fasting glucose ≥5.6 mmol/l or previously diagnosed 
diabetes, triglycerides ≥1.7 mmol/l or taking lipid-regulating medication, high-
density lipoprotein (HDL) cholesterol <1.03 mmol/l in men and <1.30 mmol/l 
in women or drug treatment for reduced HDL cholesterol. For subgroup ana-
lysis, all subjects with MS were divided into two groups: subjects without pre-
viously diagnosed diabetes, dyslipidaemia or hypertension (pre-morbid sub-
group) and subjects with a previous diagnosis of any of the above conditions 
(morbid subgroup). 
Metabolically healthy subjects were defined as subjects without impaired 
glucose regulation, without dyslipidaemia (triglycerides ≥ 1.7 mmol/L or HDL 
cholesterol < 1.3 mmol/L in women or HDL cholesterol < 1.03 mmol/l in men 
or lipid-lowering treatment), without hypertension (blood pressure ≥130/80 mmHg 
or on antihypertensive treatment) and without insulin resistance. “Metabolically 
unhealthy” was defined as having at least one of the above-mentioned four risk 
factors. The study was approved by the University of Tartu Ethics Review 
Committee on Human Research.  
Statistical analysis. Due to the slight underrepresentation of younger age-
groups (20–39 years), the prevalences of impaired glucose regulation, metabolic 
syndrome and obesity were weighted to the Estonian 20–74-year-old population 
(estimated in 2009). The prevalences of impaired glucose regulation, metabolic 
syndrome and obesity were presented as a proportion with 95% confidence 
intervals (95% CI-s). The chi-square test (with Bonferroni correction) was used 
for multiple comparison of prevalence between three age-groups. Descriptive 
statistics as medians and interquartile ranges, or as means and standard devia-
tions were calculated for the continuous variables. The Mann-Whitney U test 
was used for comparisons between different groups. Spearman partial corre-
lations coefficients were used to estimate associations between HMW adipo-
nectin and metabolic risk factors. Linear regression analysis with logarithmed 
HMW adiponectin levels was used for trend analysis over continuous age 
(adjusted for gender) and for examining association between HMW adiponectin 
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and gender (adjusted for waist circumference, BMI and use of diabetes, anti-
hypertensive and lipid-lowering medicines). Multiple logistic regression ana-
lysis was used to calculate the odd ratios (ORs) and the 95 percent confidence 
intervals (CIs) for MS risk factors. Receiver operating characteristic (ROC) 
curves were generated to compare the ability of HMW adiponectin and HOMA-
IR to discriminate between subjects with and without MS. The nonparametric 
approach was used for comparing the areas under the ROC curves (AUROC). P 
values were considered statistically significant at the 0.05 level. Statistical ana-








8.1. Prevalence of obesity, impaired glucose regulation 
and metabolic syndrome among  
the Estonian adult population 
8.1.1. Prevalence of overweight and obesity (Paper I) 
The prevalence of obesity weighted for the Estonian population in 2009 was 
32% (29% for men and 34% for women). The prevalence of obesity was signi-
ficantly higher in the oldest age group compared with the youngest age group: 
48% vs. 27%, respectively, p=0.0002. There was no significant gender diffe-
rence in the prevalence of obesity (Table 1). The prevalence of being over-
weight or obese (defined as BMI ≥25) was 67% (95% CI 62−71) in the study 
group, with 72% (95% CI 66−78) for men and 63% (95% CI 57−68) for 
women.    
 
8.1.2. Prevalence of impaired glucose regulation (Paper II) 
The prevalence of diabetes weighted for the Estonian population in 2009 was 
7%, 8% for men and 7% for women. The prevalence of diabetes increased with 
age. Nearly half (49%) of the diabetes cases had been undiagnosed until the 
subject was assessed in our study. The prevalence of IFG and IGT weighted for 
the Estonian population in 2009 was 5% and 8%, respectively. Taken together, 
our results showed that 20% of the Estonian adult population had impaired 
glucose regulation (Table 1). 
 
 
    8.1.3. Prevalence of metabolic syndrome (Paper III) 
The prevalence of MS weighted for the Estonian population in 2009 was 26%, 
29% for men and 24% for women. The prevalence of MS increased signifi-
cantly with age. The prevalence was significantly (p=0.02) higher for men when 
compared with women in the youngest age group only, and there were no 
gender-specific differences in the prevalence in the middle-aged and older age 
groups (Table 1). 
 
 
8.2. Associations between metabolic syndrome and  
insulin resistance (Paper III) 
8.2.1. Characteristics of subjects with metabolic syndrome 
Most of the subjects with MS had 3 components of the syndrome (56%), 32% 
had 4 and 12% had all 5 components. Arterial hypertension (94%), abdominal 
obesity (91%), and impaired glucose metabolism (71%) were the most common 
abnormalities in subjects of both sexes.  
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8.2.2. Characteristics of the subjects in the premorbid and  
morbid subgroups with metabolic syndrome 
The subjects of the pre-morbid subgroup were significantly younger, had lower 
systolic blood-pressure, lower BMI and smaller waist circumference (for BMI 
and waist, only the difference between the pre-morbid and the morbid men 
reached statistical significance). The HOMA-IR values and lipid levels did not 
differ between the morbid and pre-morbid subgroup (Table 3). 
 
 
8.2.3. Associations between metabolic syndrome and  
insulin resistance 
The prevalence of insulin resistance (defined as the top quartile of HOMA-IR 
for the whole study group excluding subjects with previously known diabetes) 
among subjects with and without MS was 62% (95% CI 54−70) and 12% (95% 
CI 9−16), respectively (p<0.001). The prevalence of insulin resistance among 
subjects with MS in the pre-morbid and morbid subgroups did not differ, being 
59% (95% CI 44–72%) and 64% (95% CI 53–74%), respectively (p=0.64). 
 
 
8.3. Gender differences in serum HMW adiponectin levels  
in metabolic syndrome (Paper IV) 
8.3.1. Age- and gender-specific levels  
of HMW adiponectin among the Estonian adult population 
The median HMW adiponectin level (μg/ml) was significantly higher (p<0.001) 
in women than in men (4.6, 2.9−6.5 vs. 2.5, 1.5−3.8; median, interquartile 
range, respectively). This gender difference in HMW adiponectin levels re-
mained significant also after adjustment for waist circumference, BMI and use 
of diabetes, antihypertensive and lipid-lowering medicines. The median HMW 
adiponectin levels in 10-year age groups, forming the whole study population, 
showed an increase in the older age groups for both genders. There was signi-
ficant positive association between HMW adiponectin and age in trend analysis 
(p=0.01) (Figure 1). 
 
 
8.3.2. Associations between HMW adiponectin and  
metabolic syndrome and insulin resistance 
The median (interquartile range) HMW adiponectin level was significantly 
lower for both genders among subjects with MS compared to those without MS: 
2.1 (1.3−3.0) vs. 2.8 (1.7−4.3) in men (p=0.002); and 3.1 (2.1−4.8) vs. 5.1 
(3.5−6.9) in women (p<0.001). The median (interquartile range) HOMA-IR was 
significantly higher in both genders among subjects with MS compared to those 
without MS: 2.53 (1.54−3.98) vs. 0.76 (0.47−1.27) for men (p<0.001); and 2.45 
41 
(1.45−3.52) vs. 0.89 (0.49−1.37) for women (p<0.001). The median (inter-
quartile range) HMW adiponectin level was significantly lower in both genders 
in insulin-resistant subjects compared with those without insulin resistance: 1.9 
(0.9−2.8) vs. 2.8 (1.7−4.2) in men (p<0.001) and 3.0 (2.1−4.7) vs. 5.1 (3.5−6.8) 
in women (p<0.001).  
In multiple logistic regression analysis HMW adiponectin remained signifi-
cantly inversely related to MS only for women, even after controlling for age, 
BMI, and HOMA-IR (Table 2). 
The predictive value of HMW adiponectin for MS was significantly lower 
than that of HOMA-IR. The crude AUROC for HMW adiponectin and HOMA-
IR were 0.64 vs. 0.864 in men (p<0.001) and 0.702 vs. 0.839 in women 
(p=0.0008) (Figure 2). 
After adjustment for age and BMI, the predictive value of HMW adiponectin 
remained lower than that of HOMA-IR only for men, but became equal with 
that of HOMA-IR for women. The AUROC for HMW adiponectin and HOMA-




8.4. Associations between HMW adiponectin levels and 
metabolic risk factors (Paper I) 
 We assessed correlations between HMW adiponectin and metabolic risk factors 
for the whole study group after adjusting for age. For both genders, HMW 
adiponectin was positively correlated with HDL cholesterol, and negatively 
correlated with triglycerides, waist circumference, BMI, HOMA-IR, fasting 
insulin and fasting glucose. For women only, a significant negative correlation 
was found between HMW adiponectin and systolic and diastolic blood pressure 
as well as 2-hour glucose levels on OGTT (Table 2). 
 
 
8.5. HMW adiponectin levels in metabolically healthy and 
unhealthy subjects (Paper I)                                                           
Among the whole study group, 33% of the subjects were metabolically healthy 
(151/458 subjects, whereby their prevalence was 27% for men and 37% for 
women, p-value=0.03). The percentage of the study subjects who used 
antihypertensive, lipid-lowering and antidiabetic treatment was 26.6, 3.9 and 
4.1%, respectively, and there was no gender difference. We did not find signi-
ficant associations between HMW adiponectin level and smoking or between 
HMW adiponectin level and alcohol consumption.The correlation between 
HMW adiponectin and metabolic risk factors for men was driven exclusively by 
the metabolically unhealthy subgroup. For women too, the metabolically un-
healthy subgroup again drove largely this correlation. However, also metaboli-
cally healthy women showed correlations between HMW adiponectin and HDL 
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cholesterol, triglycerides and insulin resistance (Table 2). Moreover, meta-
bolically healthy women showed substantially higher HMW adiponectin levels 
compared with metabolically unhealthy women. For men we did not find a 
significant difference in the median HMW adiponectin levels between meta-
bolically healthy and unhealthy subjects. Metabolically healthy subjects were 
significantly younger and had significantly lower HOMA-IR, waist circum-
ference and BMI compared with metabolically unhealthy subjects in both 
genders (Table 3). 
 
 
8.6. Comparison of HMW adiponectin levels between 
metabolically healthy and unhealthy overweight/obese 
subjects (Paper I)   
Among the overweight or obese subjects (BMI≥25), we compared metabolically 
healthy and unhealthy subjects. In both genders, metabolically healthy subjects 
were significantly younger and had a significantly smaller waist circumference 
and lower HOMA-IR. The HOMA-IR level in metabolically healthy over-
weight/obese subjects was comparable to that in subjects with a normal BMI. 
Among the women, metabolically healthy overweight/obese subjects had higher 
HMW adiponectin levels compared with metabolically unhealthy overweigh/ 
obese women. The HMW adiponectin levels in metabolically healthy over-
weight/obese women were comparable to those in women with a normal BMI 
(Table 4). 
Among obese subjects, 12% were metabolically healthy (19/158 subjects, 
whereby the prevalence was 11% for men (6/57 subjects) and 13% for women 
(13/101 subjects), p-value=0.9). Median HMW adiponectin levels for meta-
bolically healthy obese and metabolically unhealthy obese subjects were 3.338 
vs. 1.957 (p=0.04) for men, and 5.079 vs 3.091 μg/ml (p=0.1) for women. This 
suggests that for obese subjects of both genders, HMW adiponectin levels in 
metabolically healthy subjects are comparable to those in subjects with normal 
weight. Metabolically healthy obese subjects were significantly less insulin 
resistant than metabolically unhealthy obese subjects of both genders. There 
was no difference in mean age between metabolically healthy and unhealthy 













9.1. Prevalence of obesity, impaired glucose regulation 
and metabolic syndrome 
9.1.1. Analysis of the study population  
The study population is truly representative of the general Estonian population 
(1.34 million inhabitants in 2009). The sample of 495 subjects represented a 
mixed urban-rural population of Estonia and it was randomly drawn from the 
patient registers of four general practice centres. It is important to note that 
every resident of Estonia is in a general practitioner register either after patient´s 
personal choice or according to his/her address. All four general practitioner 
centres were situated in small residential areas and were attended by most 
inhabitants according to the population register. Due to the slight underrepre-
sentation in the younger age group (20–39 years), the prevalences of obesity, 
impaired glucose regulation and metabolic syndrome were weighted for the 
Estonian adult population (estimated in 2009).  
 
 
9.1.2. Prevalence of overweight and obesity 
In this population-based, multicentre, cross-sectional study we found that the 
prevalence of obesity among Estonian adults aged 20–74 was significantly 
higher than previously estimated: 32% (29% for men and 34% for women, 
weighted for the Estonian population in 2009). In comparison, the prevalence 
estimated by self-reported data in 2008 among subjects aged 16–64 years was 
just 17.5% for men and 18.0% for women (Tekkel et al 2009). The prevalence 
of obesity is known to increase with age and the subjects of our study group 
were slightly older. However, this slight shift in demographics is insufficient to 
explain this nearly twofold difference. Previous studies have shown that the 
prevalence of being overweight is higher if calculated from measured values as 
opposed to self-reported values (Kuczmarski et al 2001). Furthermore, non-
responders to self-reported body weight questions in health questionnaires are 
more likely to be obese (Nyholm et al 2008). These factors may partially 
explain why self-report methods underestimate the prevalence of obesity.  
Recent European studies, using objective data, have assessed the prevalence 
of obesity as being of same magnitude as we have currently found for Estonia: 
for example in Latvia 26% for men and 33% for women (Erglis et al 2012), in 
Albania 24% for men and 36% for women (Spahija et al 2012) and in Croatia 
26% for men and 34% for women (Poljicanin et al 2012). The high prevalence 
of overweight and obesity (defined as BMI ≥25) in Estonia (67%) is also 
comparable to recent prevalence rates from Latvia (68%) (Erglis et al 2012). 
Our finding has important implications for public health policy in Estonia. To 
date, many practitioners had believed that Estonia was more or less spared the 
global obesity epidemic. Our data presents contrary evidence, according to 
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which the problem of obesity is as serious in Estonia as it is in other Western 
countries, and hence this issue deserves increasing attention in the sphere of 
public health policy. 
 
 
9.1.3. Prevalence of impaired glucose regulation 
The prevalence of diabetes among adults in Estonia (7%) is comparable to that 
in other European countries (Shaw et al 2010). The current study addressed the 
knowledge gap in the prevalence of diabetes and impaired glucose regulation 
among adults in Estonia, providing more accurate estimates on the prevalence 
of these disorders than those predicted previously on the basis of extrapolated 
data. 
 
9.1.4. Prevalence of metabolic syndrome 
We estimated the age- and gender-specific prevalence of MS for 20–74-year-old 
Estonian adults according to NCEP ATP III criteria. A recent joint scientific 
statement issued by different international organisations agreed on the threshold 
values for most of the components of MS, with the exception of waist circum-
ference, for abdominal obesity. The IDF criteria define abdominal obesity at a 
lower threshold ( 94 cm in men and  80 cm in women) than the NCEP ATP 
III criteria (Alberti et al 2009). We chose to use the NCEP ATP III criteria for 
prevalence estimations as studies from Europe and the United States generally 
use higher thresholds for waist circumference (Alberti et al 2009). Moreover, a 
recent meta-analysis of nearly one million patients convincingly demonstrated a 
2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause 
mortality for individuals diagnosed with MS according to the NCEP ATP III 
criteria (Mottillo et al 2010), adding further credibility to the practical appli-
cation of the NCEP ATP III criteria. 
In our study, we found 28% of subjects to be affected by MS while the 
weighted prevalence rate for the general population was 26%. In comparison 
with the prevalence of MS in other countries, the DECODE study including 
pooled data from nine European population-based cohorts showed higher 
average prevalence of MS: 32.2% and 28.5% for men and women, respectively 
(Qiao 2006). However, the DECODE study population was notably older 
(3089 years). More recent studies from Europe that have estimated the pre-
valence according to NCEP ATP III in age groups comparable to those of our 
study population have shown quite comparable results: 25.9% in Norway 
(Hildrum et al 2007), 28.8% in Turkey (Gündogan et al 2009), and 24.7% in 
Luxembourg (Alkerwi et al 2011). Furthermore, our estimates of the prevalence 
of diabetes (7%) and impaired glucose tolerance (8%) in Estonia are also 
comparable to those found in other developed countries (Eglit et al 2011). Thus, 
the prevalence of metabolic syndrome in Estonia appears to be similar to that in 
the rest of the developed regions. 
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MS was more common in men than in the women of the younger age group 
only, followed by an equalisation of the gender-specific prevalence in the 
middle age group and thereafter. These gender-specific differences in Estonia 
are generally comparable to the patterns described from other populations 
(Cornier et al 2008). However, the difference in the prevalence between the men 
(26%) and the women (13%) in the youngest age group is more pronounced 
compared with data, for example, from the USA (Cornier et al 2008). Our 
neighbouring country Finland recently reported a similar twofold increase in the 
prevalence of MS among 24–39-year-old men in comparison with women 
(Mattsson et al 2007). These regional observations are particularly noteworthy 
given that of all countries of the European Union, gender differences in life 
expectancy are also the greatest in the Baltic States (Eurostat 2010). Our 
findings suggest that the distribution of MS between young men and women 
may contribute to the large gender related differences in life expectancy in the 
North-East of Europe, as life expectancy for these young men may be reduced 
by subsequent development of cardiovascular disease and diabetes. Further 
studies could establish whether the high prevalence of MS for young men in the 
North-East of Europe is due to genetic vulnerability, environmental influence, 
or an interaction between these two. 
 
 
9.2. Associations between metabolic syndrome and  
insulin resistance 
There is general agreement that MS denotes a high life-time risk of diabetes and 
cardiovascular disease and it has been proposed that after exclusion of indivi-
duals with established diabetes and cardiovascular disease MS should be con-
sidered a pre-morbid condition (Simmons et al 2010). In addition, a recently 
coined term “Nascent MS” denotes subjects with MS but without the con-
founding presence of diabetes and/or cardiovascular diseases (Jialal et al 2012). 
Nascent MS is associated with increased oxidative stress, increased levels of 
adipocytokines and decreased levels of adiponectin, which are related to insulin 
resistance in inflammation (Jialal et al 2012, Bremer et al 2013).  
In the context of considering MS a pre-morbid condition, we divided the 
study subjects with metabolic syndrome in to the pre-morbid and morbid 
subgroups. Comparison of these groups showed that, as expected, pre-morbid 
individuals were significantly younger than morbid subjects, and male subjects 
were significantly less obese (regarding both waist circumference and BMI). 
Despite these differences, pre-morbid subjects proved to be as insulin resistant 
as morbid subjects as estimated by HOMA-IR. This may indicate that insulin 
resistance is a hallmark of MS already in the early stage of this disorder. 
However, insulin resistance of the same magnitude in the premorbid and morbid 
subgroups with MS should be interpreted with caution, due to the therapeutic 
effects of lifestyle and medical interventions on alleviating insulin resistance in 
the morbid subgroup. Elevations of insulin concentration have been shown to 
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precede the development of diabetes and multiple metabolic disorders in large 
prospective studies (Haffner et al 1992, Tabak et al 2009). Moreover, insulin 
resistance per se is a well established independent predictor of cardiovascular 
disease (Jeppesen et al 2007, Tenenbaum et al 2007). In line with previous 
studies (Cheal et al 2004, Stern et al 2005), our results support the conclusion 
that a high proportion of insulin resistant subjects, both apparently healthy indi-
viduals and those with established cardiometabolic abnormalities, can be 
identified by simple measurements defining MS. Therefore, MS seems to 
remain a useful practical tool for early identification of apparently healthy 
individuals at a considerable risk of cardiovascular disease and diabetes. 
 
 
9.3. Gender difference in serum HMW adiponectin  
levels in metabolic syndrome 
In line with previous studies (Nishizawa et al 2002, Wang et al 2008), our 
results confirmed a clear gender difference in adiponectin levels: women had 
significantly higher HMW adiponectin level compared with men. Considering 
the gender difference in HMW adiponectin levels, we made a gender-specific 
logistic regression analysis to determine the association between HMW adipo-
nectin and MS and found that after adjustment for age, BMI and HOMA-IR, 
HMW adiponectin remained significantly associated with MS only for women. 
Similarly, a recent study from Finland in subjects with elevated blood pressure 
also demonstrated that after adjustment for BMI, the association between total 
adiponectin and presence of MS was statistically significant for women but not 
for men (Ahonen et al 2009). In addition, we found that after adjusting for age 
and BMI, HOMA-IR remained a better predictor of MS compared with HMW 
adiponectin for men, while there was no difference in this respect for women 
(estimated by AUROC). Therefore, these results demonstrate stronger relation-
ship between HMW adiponectin and MS for women. Associations between 
HMW adiponectin levels and presence of MS have been studied previously in 
Japanese (Hirose et al 2010, Kawamoto et al 2011), Caucasian American 
(Devaraj et al 2008) Japanese American (Nakashima et al 2011), Thai (Liu et al 
2007), Korean (Lee et al 2009), and Chinese subjects (Yu et al 2011). There 
have been conducted no similar European population-based surveys assessing 
the association between HMW adiponectin and MS, to the best of our know-
ledge. Associations between total adiponectin and various metabolic parameters 
in different population subgroups have been addressed in earlier Estonian 
studies (Jürimäe et al 2007, Jürimäe et al 2010), but the current study is the first 
one estimating serum HMW adiponectin level in a general population-based 
survey. As expected, we also found that MS was characterised by lower levels 
of serum HMW adiponectin and higher levels of insulin resistance as assessed 
by HOMA-IR. Accordingly, there was observed strong inverse correlation 
between insulin resistance and HMW adiponectin. It is well established that MS 
increases the risk of heart disease in both genders, although it seems to elicit a 
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greater impact in women (Ren et al 2009). Metabolic syndrome is a stronger 
predictor of cardiovascular disease in women than in men (Pischon et al 2008), 
and the effect of MS on left ventricular function and hypertrophy is greater in 
women than in men (Schillaci et al 2006). Considering the current findings 
about gender differences between HMW adiponectin and MS, we propose that 
hypoadiponectinaemia may be more strongly associated with metabolic syndro-
me in women than in men.  
 
 
9.4. Association between HMW adiponectin levels and 
metabolic risk factors  
We found HMW adiponectin to correlate positively with HDL cholesterol and 
negatively with obesity, insulin resistance, triglycerides and fasting glucose for 
both genders. For women only, we found HMW adiponectin to correlate nega-
tively with 2-hour glucose in the OGTT, as well as with systolic and diastolic 
blood pressure. These results are similar to the outcomes of Andreasson et al. 
who observed gender-related differences in the association between adiponectin 
and cardiovascular risk factors: total adiponectin was associated with blood 
lipids both in men and women, but adiponectin was associated with glucose 
homeostasis more in women than in men (Andreasson et al 2012). Our study 
adds to this literature data by describing this relationship in terms of HMW 
adiponectin, instead of total adiponectin. In contrast, in a KORA survey, total 
adiponectin correlated to various metabolic risk factors in a pattern that was 
similar for both sexes (Rathmann et al 2007). We found HMW adiponectin to 
correlate to blood pressure exclusively in women. Clinical and experimental 
studies indicate causal relationship between low adiponectin and hypertension 
(Ohashi et al 2011), but it is still unclear to what extent this applies to men as 
well as to women. On the one hand, a recent Japanese study showed that serum 
HMW adiponectin concentrations were inversely associated with blood pressure 
in the general male population (Kawamoto et al 2011b). In contrast, earlier 
studies on Japanese (Tabara et al 2008), Chinese (Yu et al 2011) and on Thai 
subjects (Liu et al 2007) found no correlation between HMW adiponectin and 
systolic blood pressure. There exist significant differences in HMW adiponectin 
levels between different ethnic groups (Khan et al 2012), and to date most of 
relevant research has been carried out on Asian populations. Our study adds 
information about associations between HMW adiponectin and blood pressure 





9.5. HMW adiponectin levels in metabolically  
healthy and unhealthy subjects 
In metabolically healthy men, no correlations were found between HMW adipo-
nectin and metabolic risk factors, with the exception of one risk factor: systolic 
blood pressure. Surprisingly, this relationship was not negative but positive. Our 
metabolically healthy group of men (n=52) had a mean systolic blood pressure 
of 119.8 ± SD 7.2 mmHg (range 88.0–129.0). On the contrary, a recent study 
from Japan found higher adiponectin to correlate with lower systolic and dias-
tolic blood pressure in normotensive people (Baden et al 2013). Associations 
between HMW adiponectin and cardiovascular disease are complex and in-
fluenced by several conditions and factors (chronic heart disease, chronic kid-
ney disease, cachexia, underlying disease state) (Okamoto et al 2011, Anto-
niades et al 2009). Therefore, this unexpected positive association between 
HMW adiponectin and systolic blood pressure in metabolically healthy men 
may be affected by other underlying factors. Unlike for metabolically healthy 
men, we found HMW adiponectin to correlate with HDL cholesterol, trigly-
cerides and insulin resistance for the metabolically healthy female subgroup. 
Comparisons of metabolically healthy and unhealthy subjects showed, as 
expected, that metabolically unhealthy subjects were significantly older, had 
significantly higher BMI, waist circumference and HOMA-IR compared with 
metabolically healthy subjects in both genders. In addition, we found that for 
women only, metabolically healthy subjects had significantly higher HMW 
adiponectin levels compared with metabolically unhealthy subjects. This result 
is in line with our previous finding that HMW adiponectin correlates with meta-
bolic risk factors for the group of metabolically healthy women but not for 
metabolically healthy men. To the best of our knowledge, previous studies have 
not described such gender differences in the relationship between HMW 
adiponectin levels and metabolic risk factors between metabolically healthy and 
unhealthy subjects. Whether and how this gender-specific difference influences 
the pathophysiologial processes through which HMW adiponectin influences 
health and disease is worthy of further study. It is known that testosterone 
reduces selectively the HMW form of adiponectin, which might contribute to 
the gender difference in adiponectin levels (Xu et al 2005). A recent study from 
Spain showed that adiponectin was related to free androgen index and sex 
hormone binding globulin levels in adolescents after adjusting for BMI and fat 
mass, suggesting an association between adiponectin and androgen bio-
availability (Riestra et al 2013). On the other hand, serum adiponectin level was 
positively correlated with testosterone concentration in ageing (50–85 years) 
men but not in women (Yasui et al 2007). Thus, other factors besides 
testosterone might also play a role in the gender difference of adiponectin levels 




9.6. Comparison of HMW adiponectin levels  
between metabolically healthy and unhealthy 
overweight/obese subjects 
A subset of obese subjects seems to be protected from obesity-related cardio-
vascular and metabolic abnormalities. Metabolically normal obesity describes 
individuals with a body mass index of ≥ 30 kg/m2 who do not have any overt 
cardiometabolic diseases such as type 2 diabetes mellitus, dyslipidaemia and 
hypertension. Components of metabolic syndrome, such as inflammatory 
markers and insulin sensitivity, have also been used to categorize subjects as 
metabolically healthy or unhealthy. However, it is not clear whether this meta-
bolically healthy obese phenotype is just an early stage in the disease process 
that will ultimately progress to metabolically unhealthy obesity, or whether 
metabolically healthy obese people are relatively protected from developing the 
co-morbidities associated with obesity for the remainder of their lives (Pataky et 
al 2010). Within our overweight sample, the metabolically healthy subgroup 
was approximately 10 years younger than the metabolically unhealthy sub-
group; it may still be that we are seeing two different snapshots of the same 
process in time, whereby metabolically healthy subjects tend to undergo tran-
sition to an increasingly metabolically unhealthy status over time. However, in 
contrast to this hypothesis, our obese sample showed similar age distributions 
for the metabolically healthy and unhealthy subjects. Hence our data does not 
allow us to refute either hypothesis. Future longitudinal studies could establish 
whether these metabolically healthy and unhealthy phenotypes are distinct only 
in time, or also by nature.  
While there exist no established criteria for the definition of metabolically 
healthy obese individuals (Alam et al 2012), previous studies have reported that 
these individuals constitute approximately 6−35% of all obese subjects de-
pending on the definition (Pataky et al 2010). A recent study from Finland 
showed that among obese subjects aged 45–74, the prevalence of the meta-
bolically healthy obese phenotype, which was defined as the absence of meta-
bolic syndrome, was 9.2% for men and 16.4% for women (Pajunen et al 2011). 
We defined the metabolically healthy status by strict criteria (subjects without 
impaired glucose regulation, dyslipidaemia, hypertension or insulin resistance) 
and found that 12% of obese subjects were metabolically healthy. Further 
analysis showed that in both genders, these metabolically healthy obese subjects 
had HMW adiponectin levels comparable to those of normal weight subjects. 
These results are in line with the outcomes of a recent study from Poland which 
did not find differences in HMW adiponectin concentrations between over-
weight or obese but metabolically healthy women, and normal weight controls, 
either (Bik et al 2010). Our data adds useful information to the notion that this 
phenomenon also exists in the case of obese but metabolically healthy Cau-
casian men. We found that among women with BMI ≥ 25 kg/m2, HMW 
adiponectin levels were higher in metabolically healthy women compared with 
metabolically unhealthy women. We did not find a comparable difference for 
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men. However, among obese men, metabolically healthy men had significantly 
higher HMW adiponectin levels compared with metabolically unhealthy men. 
While we cannot explain this discrepancy, we are aware that the pathogenesis of 
metabolic disease is complex and includes various factors that are beyond the 
scope of this study. Kim et al have shown that mice that lacked leptine while 
overexpressing adiponectin had significantly higher levels of adipose tissue than 
their ob/ob littermates, but an improved metabolic profile (Kim et al 2007). 
Several other genetically modified murine models of obesity, with preserved 
insulin sensitivity, have been identified and common features of most of these 
models are an increased mass of non-visceral adipose tissue, a metabolically 
beneficial adipokine pattern, and a low amount of lipid deposition in the liver 
(Stefan et al 2013). Thus, there are many other adipocytokines, besides adipo-
nectin, which modify the pathogenesis of metabolic disorders. Moreover, they 
are likely to influence each other’s expression and production (Hajer et al 2008, 
Aprahamian et al 2011, Mattu et al 2013). We measured only one adipocytokine 
isoform (HMW adiponectin) and hence only focused on one aspect of the 
complex association between adipose tissue dysfunction and metabolic risk 
factors. Our study also had the following limitations: the possible complex 
effect of other underlying diseases (and medications used for other diseases) on 
HMW adiponectin levels could not be excluded; the metabolically healthy 
obese subgroup was very small; the definitions of the metabolically healthy 
obese phenotype have not been standardized; and BMI as a measure of obesity 
has limitations because it cannot distinguish between fat tissue and lean tissue. 
Despite these limitations, the study had also several strengths: the population-
based approach; measuring not total but HMW adiponectin; strict criteria to 
define metabolically healthy subgroups; and impaired glucose regulation 





















1. The prevalence of obesity in Estonian adult population was 32%. This 
indicator is significantly higher than previously estimated but comparable 
with recently reported data from other European countries.  
2. Of the Estonian adult population 20% had impaired glucose regulation: the 
prevalence of IFG, IGT and diabetes was 5, 8 and 7%, respectively. This 
result is comparable to that reported from other European countries. 
3. The prevalence of metabolic syndrome among the Estonian adult population 
was 26%, which is comparable to that in other European countries. How-
ever, in younger age men in Estonia had a significantly higher prevalence of 
metabolic syndrome compared with women (26% versus 13%, respecti-
vely). 
4. The prevalence of insulin resistance was 5 times higher in subjects with 
metabolic syndrome but was not different between the premorbid and the 
morbid subgroups. This suggests that the concept of metabolic syndrome 
may be practically useful in early prediction of the life-time risk of 
cardiovascular disease and diabetes. 
5. The HMW adiponectin level was significantly lower in all subjects with 
metabolic syndrome compared with those without metabolic syndrome. 
6. Hypoadiponectinaemia is more strongly associated with metabolic syndro-
me in women than in men. Further studies are necessary to confirm these 
results in other populations and to elucidate whether adiponectin can 
influence the pathogenetic mechanisms of cardiometabolic diseases in a 
gender-specific manner in humans. 
7. HMW adiponectin correlated positively with HDL cholesterol and negati-
vely with obesity, insulin resistance, triglycerides and fasting glucose for 
both genders. For women only, we found HMW adiponectin to correlate 
negatively with 2-hour glucose in the OGTT, as well as with systolic and 
diastolic blood pressure.  
8. For women only, metabolically healthy subjects had significantly higher 
HMW adiponectin levels compared with metabolically unhealthy subjects. 
9. For metabolically healthy women, HMW adiponectin levels were associated 
with various metabolic risk factors but this association was not found for 
metabolically healthy men. 
10. Twelve percent of obese subjects were metabolically healthy and this 
phenotype was characterized by HMW adiponectin levels similar to those 





11. SUMMARY IN ESTONIAN 
Rasvumine, glükoosiregulatsiooni häired, metaboolne 




Viimase 30 aasta jooksul on rasvumise levimus maailmas kahekordistunud: 
2008. aastal hinnati rasvumise levimuseks maailmas 10% meestel ja 14% 
naistel, kuid 1980. aastal vastavalt 5% ja 8% (Finucane jt 2011). Ülekaalulisuse 
ja rasvumise levimuse kiire tõus kogu maailmas viitab sellele, et põhjused on 
pigem seotud keskkonna, toitumise ja elustiili kui geneetiliste muutustega 
(Murphy jt 2013). Geneetiliste faktorite mõju tõttu on siiski ülekaalulisuse risk 
ja selle ulatus sarnases keskkonnas inimestel erinev (Haslam jt 2005, Walley jt 
2009, Dixon 2010). Rasvumine on seotud paljude tervisehäiretega, nagu hüper-
tensioon, diabeet, düslipideemia, koronaarhaigus, südamepuudulikkus, maksa-
haigused, astma, sapikivitõbi, luu- ja liigeshaigused, depressioon ning pahaloo-
mulised kasvajad (Clement jt 2010). Postiküsitluse tulemuste alusel hinnati 
2008. aastal rasvumise levimuseks Eestis 16–64 aastaste isikute hulgas 18% 
(Tekkel jt 2008), kuid objektiivsetel mõõtmistel põhinevat populatsioonipõhist 
uuringut ei ole Eestis varem läbi viidud.  
Metaboolne sündroom on riskifaktorite (rasvumine, glükoosiregulatsiooni 
häired, hüpertensioon ja düslipideemia) kogum, mille puhul esineb vähemalt 
viis korda kõrgem risk haigestuda 2. tüüpi diabeeti ja kaks korda kõrgem 
südameveresoonkonna haiguste risk (Eckel jt 2005, Mottillo jt 2010). Seoses 
rasvumise levimuse kasvuga suureneb ka metaboolse sündroomi levimus kogu 
maailmas (Cornier jt 2008). Üheksa Euroopa riigi andmete põhjal hinnati meta-
boolse sündroomi levimuseks meeste hulgas 32% ja naiste hulgas 29% (Qiao jt 
2006). Eestis pole varem metaboolse sündroomi levimust uuritud. Kuigi meta-
boolse sündroomi patofüsioloogilised mehhanismid ei ole selged, peetakse või-
malikuks keskseks mehhanismiks siiski abdominaalse rasvumisega kaasnevat 
insuliinresistentsust (Eckel jt 2005, Cornier jt 2008). Sellest tulenevalt on kõige 
olulisemaks metaboolse sündroomi kujunemist mõjutavaks riskifaktoriks rasvu-
mine (Cameron jt 2009). Rasvumisel ja insuliinresistentsusel on oluline roll ka 
2. tüüpi diabeedi kujunemisel (Murphy jt 2013). Seoses rasvumise leviku kas-
vuga tõuseb kogu maailmas ka glükoosiregulatsiooni häirete levimus (Shaw jt 
2010). Eesti täiskasvanud elanikkonna kohta andmed diabeedi levimuse hinda-
miseks seni puudusid. Globaalsetes raportites hinnati ekstrapoleeritud Poola 
andmetele tuginedes diabeedi levimuseks Eestis 2000. aastal 4,4% (Wild jt 
2004) ja 2010. aastal 9,9% (Shaw jt 2010). 2006. aastal läbiviidud väiksema 
populatsioonipõhise uuringu põhjal leiti, et diabeedi levimus Eesti ühes piir-
konnas, Väike-Maarjas, oli 8,7% (Rajasalu jt 2008). Käesolev populatsiooni-
põhine uuring on esimene, mille tulemuste põhjal saab hinnata glükoosiregu-
latsiooni häirete reaalset levimust Eesti täiskasvanud rahvastikus. Viimases 
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Rahvusvahelise Diabeedi Föderatsiooni Diabeediatlases on käesolevat uuringut 
ka ühe allikana kasutatud ja diabeedi levimuseks Eesti täiskasvanud rahvastikus 
on märgitud 7,7% (International Diabetes Federation 2013). 
Rasvkude on oluline endokriinorgan, mis toodab paljusid bioaktiivseid 
mediaatoreid ja hormoone (adipotsütokiine), mis mõjutavad hemostaasi, vere-
rõhku, lipiidide ja glükoosi metabolismi ning ka põletiku ja ateroskleroosi 
kujunemist (Rabe jt 2008). Adiponektiin on rasvkoes toodetav hormoon, millel 
on insuliinitundlikkust parandavad, põletikuvastased, ateroskleroosivastased ja 
kardioprotektiivsed toimed ning vastupidiselt teistele rasvkoes toodetavatele 
hormoonidele on adiponektiini tase rasvumise ja sellega seotud seisundite puhul 
vähenenud (Scherer 2006). Adiponektiini sekreteeritakse madala ja kõrge 
molekulaarkaaluga isomeeridena, metaboolselt kõige aktiivsemaks peetakse just 
kõrgmolekulaarkaaluga (KMK) adiponektiini (Simpson jt 2010). KMK adipo-
nektiini taseme osas on selge sooline erinevus: võrreldes meestega on naistel 
KMK adiponektiini tase oluliselt kõrgem (Xu jt 2005).  
Enamasti on rasvumine seotud mitmete metaboolsete häirete kujunemisega, 
kuid siiski esineb rasvunute hulgas alagrupp, kellel metaboolseid häireid ei leita 
ja sellise fenotüübiga isikuid nimetatakse metaboolselt terveteks rasvunuteks 
(Pataky jt 2010). Võrreldes rasvunutega, kellel esineb metaboolseid häireid, on 
metaboolselt tervetel rasvunutel suurem nahaaluse ja väiksem vistseraalse rasva 
osakaal ning vähem ektoopilisi rasvaladestusi maksas ja skeletilihastes (Stefan 
jt 2013). Lisaks on leitud, et metaboolselt tervetel rasvunutel on võrreldes meta-
boolsete häiretega rasvunutega ka suurem insuliinitundlikkus, madalam 
põletikumarkerite tase, väiksem intima-media paksus ning kõrgem adiponektiini 
tase (Primeau jt 2011). Veelgi enam, on leitud, et metaboolselt tervete rasvunute 
adiponektiini tase on võrreldav normaakaaluliste isikute adiponektiini tasemega 
(Aguilar-Salinas jt 2008, Doumatey jt 2012). KMK adiponektiini taseme kohta 
metaboolselt tervetel rasvunutel on andmeid vähe – meie teada on ainult mõned 
uuringud, mille käigus on hinnatud KMK adiponektiini taset metaboolselt 
tervetel rasvunud naistel (Bik jt 2010, Elisha jt 2010).  
 
 
11.2. Uuringu eesmärgid 
1) Hinnata rasvumise, glükoosiregulatsiooni häirete ja metaboolse sündroomi 
levimust Eesti täiskasvanud elanikkonnas. 
2) Analüüsida insuliinresistentsuse ja metaboolse sündroomi vaheliseid seoseid. 
3) Kirjeldada soospetsiifilisi seoseid KMK adiponektiini taseme ja metaboolse 
sündroomi vahel. 
4) Analüüsida metaboolsete riskifaktorite ja KMK adiponektiini taseme vahe-
liseid soospetsiifiliseid seoseid. 






11.3. Uuritavad ja meetodid 
Rahvastikupõhine läbilõikeuuring viidi läbi kolmes Eesti maakonnas (Viljandi-, 
Põlva- ja Tartumaal) aastatel 2008–2009. Uuritavad valiti juhuslikult nelja pere-
arsti nimistutest ning kutsuti uuringust osa võtma kirja teel (vastamismäär 
53%). Lõpliku uuringugrupi moodustasid 495 uuritavat (214 meest, 281 naist) 
vanuses 20–74 aastat ja selle struktuur vastas 2009. aastal hinnatud Eesti 
rahvastiku vanuselisele ja soolisele struktuurile. Uuritavatel mõõdeti vererõhk, 
vööümbermõõt, pikkus ja kaal ning nad täitsid ankeedi haiguste ja riskifaktorite 
kohta. Kõikidel uuritavatel, kellel diabeeti varem diagnoositud ei olnud, tehti 
glükoositaluvuse proov ja kõikidel määrati paastuplasmast glükoosi, üldkoleste-
rooli, HDL-kolesterooli, triglütseriidide, insuliini ja KMK adiponektiini väär-
tused. Rasvumist, ülekaalulisust ja glükoositaluvuse häireid diagnoositi Maa-
ilma Terviseorganisatsiooni (WHO) kriteeriumite alusel. Metaboolse sündroomi 
hindamiseks kasutati Rahvusvahelise Kolesterooli Õppeprogrammi Täiskasva-
nute III Ravipaneeli (NCEP ATP III) kriteeriume. Insuliinresistentsust defi-
neeriti kui homeostaasi mudeli (HOMA) ülemist kvartiili kogu uuringugrupis 
(analüüsist jäeti välja varem diagnoositud diabeediga uuritavad). Metaboolse 
sündroomiga uuritavad jagati kahte alagruppi: esimese grupi moodustasid 
isikud, kellel ei olnud varem diabeeti, düslipideemiat ega hüpertensiooni diag-
noositud, ja teise gruppi jäid uuritavad, kellel esines kasvõi üks eelpool-
nimetatud häiretest. Kogu uuringugrupi lõikes jagati uuritavad metaboolselt 
terveteks (isikud, kellel ei esinenud glükoosiregulatsiooni häiret, düslipi-
deemiat, hüpertensiooni ega insuliinresistentsust) ja metaboolsete häiretega 
grupiks (uuritavad, kellel esines vähemalt üks eelpoolnimetatud häiretest).  
Statistilises analüüsis kasutati vabavaralist tarkvarapaketti R (versioon 
2.15.3). Leiti rasvumise, glükoosiregulatsiooni häirete ja metaboolse sündroomi 
levimus ja 2009. aastal hinnatud Eesti rahvastiku struktuurile kaalutud levimus 
(%) koos 95% usalduspiiridega. Levimuse võrdlemiseks kolme vanusegrupi 
vahel kasutati hii-ruut testi koos Bonferroni korrektsiooniga. Pidevate tunnuste 
esitamiseks arvutati mediaanid ja kvartiilidevahed või keskväärtused ja 
standardhälbed. Mann-Whitney U testiga võrreldi erinevaid alagruppe. Spear-
mani osalist korrelatsioonikordajat kasutati kõrgmolekulaarkaaluga adiponek-
tiini ja metaboolsete rikifaktorite vaheliste seoste hindamiseks. Mitmest logisti-
list regressioonianalüüsi kasutati metaboolse sündroomi riskifaktorite hinda-
miseks. ROC-kõverate abil võrreldi kõrgmolekulaarkaaluga adiponektiini ja 
insuliinresistentsuse homeostaasi mudeli ennustavat väärtust metaboolse sünd-
roomi hindamisel. Lubatud statistilise vea piiriks valiti 5% (p<0.05). Uuringul 





Rasvumise, glükoosiregulatsiooni häirete ja metaboolse sündroomi levimus 
Rasvumise kaalutud levimus oli 32%. Meeste ja naiste vahel statistiliselt olulist 
erinevust ei esinenud. Diabeedi kaalutud levimus oli 7%, olulist soolist eri-
nevust ei leitud. Diabeedi levimus suurenes vanuse kasvades ning peaaegu 
pooled (49%) diabeedijuhtudest olid varem diagnoosimata. Paastuglükoosi 
häire ja glükoositaluvuse häire kaalutud levimused olid vastavalt 5% ning 8%. 
Glükoosiregulatsiooni häire esines 20%-l uuritavatest.      
Metaboolse sündroomi kaalutud levimus oli 26% ja suurenes oluliselt vanu-
sega. Ainuke sooline erinevus metaboolse sündroomi levimuse osas oli noori-
mas vanusegrupis: meestel esines metaboolset sündroomi võrreldes naistega 
oluliselt rohkem (vastavalt 26% versus 13%). 
 
Seosed metaboolse sündoomi ja insuliinresistentsuse vahel.  
Metaboolse sündroomi alagruppide võrdlus 
Metaboolse sündroomiga isikutest olid insuliinresistentsed 62% ja ilma meta-
boolse sündroomita 12% uuritavatest. Metaboolse sündroomiga uuritavad, 
kellel varem düslipideemiat, diabeeti ega hüpertensiooni diagnoositud ei olnud, 
olid oluliselt nooremad, madalama süstoolse vererõhu, väiksema kehamassi-
indeksi ja vööümbermõõduga kui need, kellel oli varasemalt diagnoositud 
kasvõi üks nimetatud häiretest. Metaboolse sündroomi alagrupid ei erinenud 
lipiidide väärtuste ega insuliinresistentsuse poolest.  
 
KMK adiponektiini soo- ja vanusespetsiifilised erinevused 
Meestega võrreldes oli naistel KMK adiponektiini tase oluliselt kõrgem. Antud 
sooline erinevus jäi kehtima ka peale kohandamist vööümbermõõdu, keha-
massiindeksi ning diabeedi-, vererõhu- ja lipiide langetavate ravimite suhtes. 
KMK adiponektiini ja vanuse vahel oli statistiliselt oluline positiivne seos.  
 
KMK adiponektiini seosed metaboolse sündroomi ja insuliinresistentsusega 
Metaboolse sündroomiga isikute hulgas oli KMK adiponektiini tase nii naistel 
kui meestel oluliselt madalam, võrreldes uuritavatega, kellel metaboolset sünd-
roomi ei esinenud. Peale kohandamist vanuse, kehamassiindeksi ja insuliin-
resistentsuse suhtes jäi pöördvõrdeline seos KMK adiponektiini ja metaboolse 
sündroomi vahel oluliseks ainult naistel. ROC-kõverate analüüs näitas, et 
homeostaasi insuliinresistentsuse mudel prognoosis nii meestel kui naistel meta-
boolse sündroomi esinemist täpsemini kui KMK adiponektiin. Peale kohan-
damist vanuse ja kehamassiindeksi suhtes jäi meestel endiselt homeostaasi 








KMK adiponektiini seosed metaboolsete riskifaktoritega 
Seoseid hinnati kohandatuna vanusele. Nii meestel kui naistel oli KMK adipo-
nektiin positiivselt seotud HDL-kolesterooliga ning negatiivselt triglütseriidide, 
vööümbermõõdu, kehamassiindeksi, homeostaasi insuliinresistentsuse mudeli, 
paastuinsuliini ja paastuglükoosiga. Naistel esines lisaks veel negatiivne seos 
kõrgmolekulaarkaaluga adiponektiini ja süstoolse ning diastoolse vererõhu ja 
glükoositaluvuse proovis 2 tunni veresuhkru väärtuse vahel. 
 
KMK adiponektiini tase metaboolsete häiretega ja häireteta isikutel  
33% uuritavatest (27% meestest ja 37% naistest) ei esinenud metaboolseid 
häireid. Antihüpertensiivseid ravimeid tarvitas 27%, statiine 4% ja diabeedi-
ravimeid 4% uuritavatest ning ravimite tarvitamise osas soolist erinevust ei 
olnud. Suitsetamisel ja alkoholitarbimisel olulist seost KMK adiponektiini tase-
mega ei leitud. Meeste hulgas esinesid seosed metaboolsete riskifaktorite ja 
KMK adiponektiini vahel ainult metaboolsete häiretega isikute alagrupis, kuid 
naistel lisaks ka metaboolsete häireteta alagrupis. Metaboolsete häireteta naistel 
oli KMK adiponektiini tase oluliselt kõrgem kui metaboolsete häiretega naistel. 
Meestel sarnast erinevust ei leitud. Nii meeste kui naiste puhul olid meta-
boolsete häireteta isikud, võrreldes metaboolsete häiretega isikutega, oluliselt 
nooremad, väiksema vööümbermõõdu ja madalama kehamassiindeksiga. 
 
KMK adiponektiini tase metaboolsete häiretega ja häireteta ülekaalulistel 
ja rasvunud uuritavatel 
Nii meeste kui naiste hulgas olid kehamassiindeksiga ≥ 25 kg/m2 metaboolsete 
häireteta uuritavad oluliselt nooremad ja väiksema vööümbermõõduga kui 
metaboolsete häiretega uuritavad. Insuliinresistentsuse osas olid metaboolsete 
häireteta uuritavad võrreldavad normaalkaaluliste isikutega. KMK adiponektiin 
oli kehamassiindeksiga ≥ 25 kg/m2 metaboolselt tervetel naistel, võrreldes 
metaboolsete häiretega naistega, oluliselt kõrgem ja samas võrreldav normaal-
kaaluliste naistega. Metaboolselt tervete rasvunute osakaal kõigist rasvunutest 
oli 12%, mis ei erinenud meeste ega naiste osas. Metaboolselt tervete rasvunute 
KMK adiponektiini tase oli võrreldav normaalkaaluliste uuritavate omaga nii 
meestel kui naistel. Metaboolselt terved rasvunud olid võrreldes metaboolsete 
häiretega rasvunutega oluliselt vähem insuliinresistentsed. Keskmise vanuses 




1)  Rasvumise levimus Eesti täiskasvanud elanikkonnas oli 32%. See on oluli-
selt kõrgem kui varasemalt hinnatud, kuid võrreldav hiljuti avaldatud and-
metega teistest Euroopa riikidest. 
2)  20% Eesti täiskasvanud elanikkonnast esines glükoosiregulatsiooni häire: 
5% paastuglükoosi häire, 8% glükoositaluvuse häire ja 7% diabeet. See 
tulemus on võrreldav teistes Euroopa riikides saadud tulemustega. 
3)  Metaboolse sündroomi levimus Eesti täiskasvanud rahvastikus oli 26%, mis 
on sarnane teiste Euroopa riikide vastavate näitajatega. Nooremate meeste 
seas oli metaboolse sündroomi levimus nooremate naistega võrreldes 
oluliselt kõrgem (vastavalt 26% versus 13%).  
4)  Metaboolse sündroomiga uuritavate hulgas oli insuliinresistentsuse levimus 
viis korda kõrgem kui isikutel, kellel metaboolset sündroomi ei esinenud. 
Metaboolse sündroomiga uuritavate alagrupp, kus varasemalt hüperten-
siooni, diabeeti ega düslipideemiat diagnoositud ei olnud, ei erinenud insu-
liinresistentsuse poolest alagrupist, kus nimetatud häired olid juba vara-
semalt diagnoositud. Seetõttu aitab metaboolse sündroomi diagnoosimine 
kardiovaskulaarhaiguse ja diabeedi riski hinnata võimalikult vara.   
5)  KMK adiponektiini tase oli metaboolse sündroomiga uuritavate hulgas 
oluliselt madalam kui isikutel, kellel metaboolset sündroomi ei esinenud.  
6)  Hüpoadiponektineemia ja metaboolse sündroomi vaheline seos oli naistel 
meestega võrreldes tugevam. Vajalikud on edasised uuringud, et seda tule-
must ka teistes rahvastikurühmades kinnitada ja selgitada, kas adiponektiin 
võib mõjutada kardiometaboolsete haiguste patogeneetilisi mehhanisme 
soospetsiifiliselt. 
7)  Nii naistel kui meestel oli KMK adiponektiini ja HDL-kolesterooli vahel 
positiivne ning KMK adiponektiini ja rasvumise, insuliinresistentsuse, 
triglütseriidide ja paastuglükoosi vahel negatiivne seos. Ainult naistel esines 
lisaks ka negatiivne seos KMK adiponektiini ja 2 tunni glükoosi väärtusega 
glükoositaluvuse proovil ning süstoolse ja diastoolse vererõhuga. 
8)  Ainult naiste hulgas oli metaboolsetelt tervetel uuritavatel KMK adipo-
nektiini tase metaboolsete häiretega isikutega võrreldes oluliselt kõrgem.  
9)  KMK adiponektiini tase oli seotud mitmete metaboolsete riskifaktoritega 
ainult metaboolselt tervete naiste hulgas. 
10) 12% rasvunutest olid metaboolselt terved ja nende KMK adiponektiini tase 
oli sarnane normaalkaaluliste isikute KMK adiponektiini tasemega nii 
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